Faculty Collaboration Database

1. Hamadani M, Kharfan-Dabaja M, Kamble R, Awab A, William K, Ozer H Primary Malignant Lymphoma of the Uterus. An Extranodal Lymphoma with an Ominous Five Year Survival. Pakistan Journal of Radiology. 2004 October-December;15(4):11-17

2. Hamadani M, Tfayli A, Sethi S, Awab A, Hamdani N. Granulocytic sarcoma manifesting as multiple skeletal lesions. Am J Med Sci. 2005 Sep;330(3):139-43.

3. Kamble RT, Hamadani M, Selby GB. Increased mean corpuscular volume after autologous hematopoietic stem cell transplantation: incidence and significance. Biol Blood Marrow Transplant. 2006 Jan;12(1):111-2.

4. Kamble RT, Hamadani M, Selby GB. Delayed myeloid engraftment due to vancomycin in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2006 Apr;57(4):795-6.

5. Hamadani M, Kharfan-Dabaja M, Kamble R, Kern W, Ozer H. Marginal zone B-cell lymphoma of the uterus: a case report and review of the literature. J Okla State Med Assoc. 2006 Apr;99(4):154-6.

6. Hamadani M, Awab A, Rashid A, Ali T, Brown B. Fibrous dysplasia protuberans in a patient with McCune-Albright syndrome. J Coll Physicians Surg Pak. 2006 May;16(5):376-7.

7. Hamadani M, Awab A, Chaudhary L, Tfayli A. Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy. J Oncol Pharm Pract. 2006 Jun;12(2):67-8.

8. Awab A, Hamadani M, Sud B, Voskuhl GW. Infected atrial myxoma. Med J Aust. 2006 Sep 18;185(6):332.

9. Awab A, Hamadani M, Saya S, Whitsett T. Early detection of digitalis-induced nonocclusive mesenteric ischemia using Doppler ultrasonography. South Med J. 2006 Oct;99(10):1142.

10. Hamadani M, Awan F. Role of thiamine in managing ifosfamide-induced encephalopathy. J Oncol Pharm Pract. 2006 Dec;12(4):237-9.

11. Tfayli A, Selby G, Maqbool F, Bierbaum W, Hamadani M. Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease. Am J Hematol. 2006 Dec;81(12):959-62.

12. Hamadani M, Chaudhary L. McCune-Albright syndrome. Med J Aust. 2006 Dec 4-18;185(11-12):597.

13. Hamadani M, Martin LK, Benson DM, Copelan EA, Devine SM, Hofmeister CC. Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR. Bone Marrow Transplant. 2007 Feb;39(4):249-51.

14. Ali T, Hasan M, Hamadani M, Harty RF. Gastroparesis. South Med J. 2007 Mar;100(3):281-6.

15. Awan F, Hamadani M. Gastrointestinal chronic graft-versus-host disease: management options. J Oncol Pharm Pract. 2007 Mar;13(1):49-51.

16. Hamadani M, Benson DM Jr, Copelan EA. Thalidomide-induced fulminant hepatic failure. Mayo Clin Proc. 2007 May;82(5):638.

17. Hamadani M, Chaudhary L, Awan FT, Khan JK, Kojouri K, Ozer H, Tfayli A. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? J Oncol Pharm Pract. 2007 Jun;13(2):69-75.

18. Awan F, Hamadani M, Devine S. Paraneoplastic Sweet's syndrome and the pathergy phenomenon. Ann Hematol. 2007 Aug;86(8):613-4.

19. Rashid A, Afaq A, Hamadani M, Warraich J, Hennebry T. An unusual etiology of chest pain. J Okla State Med Assoc. 2007 Sep;100(9):352-3.

20. Awab A, Hamadani M, Peyton M, Brown B. False-negative PET scan with bronchioloalveolar carcinoma: an important diagnostic caveat. Am J Med Sci. 2007 Oct;334(4):311-3.

21. Vrindavanam N, Hamadani M, Steele B, Awan F, Suster S, Benson DM Jr. Dramatic response to single-agent rituximab in a patient with intravascular lymphoma. Am J Hematol. 2007 Dec;82(12):1120-1.

22. Hamadani M, Magro CM, Porcu P. CD4+ CD56+ haematodermic tumour (plasmacytoid dendritic cell neoplasm). Br J Haematol. 2008 Jan;140(2):122.

23. Hamadani M, Benson DM Jr, Blum W, Garzon R, Devine SM. Pulmonary Nocardia and Aspergillus co-infection in a patient with chronic graft-versus-host disease. Transpl Infect Dis. 2008 Feb;10(1):24-6.

24. Hamadani M, Hade E, Benson DM Jr, Hofmeister CC. The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma. Biol Blood Marrow Transplant. 2008 Mar;14(3):351-2.

25. Hamadani M, Kraut EH. Review: isolated skeletal involvement in hairy cell leukemia. Clin Adv Hematol Oncol. 2008 Apr;6(4):294-6.

26. Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Blum KA, Devine SM. Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. Biol Blood Marrow Transplant. 2008 Apr;14(4):480-3.

27. Hamadani M, Awan FT, Devine SM. The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. Blood. 2008 Apr 01;111(7):3901-2.

28. Hamadani M, Awan FT, Copelan EA. Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. Biol Blood Marrow Transplant. 2008 May;14(5):556-67.

29. Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, Penza S, Lin TS, Klisovic R, Marcucci G, Farag SS, Devine SM. Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. Biol Blood Marrow Transplant. 2008 Jul;14(7):783-9. PMCID: PMC4100722

30. Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Benson DM, Blum KA, Devine SM. Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Leuk Lymphoma. 2008 Oct;49(10):1893-8.

31. Ferreri AJ, Dognini GP, Govi S, Crocchiolo R, Bouzani M, Bollinger CR, D'Incan M, Delaporte E, Hamadani M, Jardin F, Martusewicz-Boros M, Montanari M, Szomor A, Zucca E, Cavalli F, Ponzoni M. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? J Clin Oncol. 2008 Nov 01;26(31):5134-6; author reply 5136-7.

32. Hamadani M, Benson DM Jr, Lin TS, Porcu P, Blum KA, Devine SM. High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Eur J Haematol. 2008 Dec;81(6):425-31.

33. Hamadani M, Blum W Role of hematopoietic stem cell transplantation in adults with acute myeloid leukemia. Clinical Leukemia. Hamadani M., Blum W.: “Role of hematopoietic stem cell transplantation in adults with acute myeloid leukemia.” Clinical Leukemia. 2009 February;3(1):47-57

34. Blum KA, Hamadani M, Phillips GS, Lozanski G, Johnson AJ, Lucas DM, Smith LL, Baiocchi R, Lin TS, Porcu P, Devine SM, Byrd JC. Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2009 Mar;50(3):349-56. PMCID: PMC3695225

35. Hamadani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant. 2009 May;15(5):547-53. PMCID: PMC3953134

36. Hamadani M, Devine SM. Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can. Blood. 2009 Sep 17;114(12):2564-6.

37. Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O'Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2009 Nov;15(11):1422-30. PMCID: PMC3953136

38. Pant S, Hamadani M, Dodds AJ, Szer J, Crilley PA, Stevenson D, Phillips G, Elder P, Nivison-Smith I, Avalos BR, Penza S, Topolsky D, Sobecks R, Kalaycio M, Bolwell BJ, Copelan EA. Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia. Br J Haematol. 2010 Feb;148(4):623-6.

39. Benson DM Jr, Panzner K, Hamadani M, Hofmeister CC, Bakan CE, Smith MK, Elder P, Krugh D, O'Donnell L, Devine SM. Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. Leuk Lymphoma. 2010 Feb;51(2):243-51. PMCID: PMC3557809

40. Hamadani M, Awan F, Villalona-Calero MA. Malignant thymoma with immunodeficiency (Good syndrome) associated with mucormycosis. Am J Clin Oncol. 2010 Feb;33(1):109.

41. Hamadani M, Awan FT. Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. Hematol Oncol. 2010 Mar;28(1):3-12.

42. Hamadani M, Craig M, Awan FT, Devine SM. How we approach patient evaluation for hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010 Aug;45(8):1259-68.

43. Christian B, Zhao W, Hamadani M, Sotomayor EM, Navarro W, Devine SM, Racke F, Blum KA. Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor. J Clin Oncol. 2010 Nov 01;28(31):e629-32.

44. Hamadani M, Craig MD, Gibson LF, Remick SC. The evolving role of statins in hematopoietic stem and progenitor cell transplantation. Am J Blood Res. 2011;1(1):57-64. PMCID: PMC3301410

45. Kanate AS, Craig M, Cumpston A, Saad A, Hobbs G, Leadmon S, Bunner P, Watkins K, Bulian D, Gibson L, Abraham J, Remick SC, Hamadani M. Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2011;4(4):149-56.

46. Liu K, Anthony BA, Yearsly MM, Hamadani M, Gaughan A, Wang JJ, Devine SM, Hadley GA. CD103 deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cells. PLoS One. 2011;6(7):e21968. PMCID: PMC3136479

47. Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B, Freytes CO, Vogl DT, Vesole DH, Lazarus HM, Meehan KR, Hamadani M, Lill M, Callander NS, Majhail NS, Wiernik PH, Nath R, Kamble RT, Vij R, Kyle RA, Gale RP, Hari PN. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood. 2011 Aug 18;118(7):1979-88. PMCID: PMC3158724

48. Hamadani M, Mohty M, Kharfan-Dabaja MA. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. Cancer Control. 2011 Oct;18(4):237-45.

49. Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM. Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. Hematol Oncol. 2011 Dec;29(4):202-10. PMCID: PMC3557914

50. Chaudhary L, Hamadani M Management strategies for follicular lymphoma patients in remission after modern frontline chemoimmunotherapies. Journal of Blood Disorders & Transfusion. Chaudhary L, Hamadani M (2012) Management Strategies for Follicular Lymphoma patients in Remission after Modern Frontline Chemoimmunotherapies. J Blood Disorders Transf 3:e105

51. Kanate AS, Kharfan-Dabaja MA, Hamadani M. Controversies and recent advances in hematopoietic cell transplantation for follicular non-hodgkin lymphoma. Bone Marrow Res. 2012;2012:897215. PMCID: PMC3477524

52. Awan FT, Kochuparambil ST, Deremer D, Cumpston A, Craig M, Jillella A, Hamadani M. Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization. J Oncol. 2012;2012:931071. PMCID: PMC3335320

53. Awan FT, Osman S, Kochuparambil ST, Gibson L, Remick SC, Abraham J, Craig M, Jillella A, Hamadani M. Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation. Bone Marrow Transplant. 2012 Jan;47(1):146-8.

54. Ranganathan P, Heaphy CE, Costinean S, Stauffer N, Na C, Hamadani M, Santhanam R, Mao C, Taylor PA, Sandhu S, He G, Shana'ah A, Nuovo GJ, Lagana A, Cascione L, Obad S, Broom O, Kauppinen S, Byrd JC, Caligiuri M, Perrotti D, Hadley GA, Marcucci G, Devine SM, Blazar BR, Croce CM, Garzon R. Regulation of acute graft-versus-host disease by microRNA-155. Blood. 2012 May 17;119(20):4786-97. PMCID: PMC3367879

55. Hamadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K, Morrison D, Speir E, Deremer D, Kota V, Jillella A, Craig M, Awan F. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Biol Blood Marrow Transplant. 2012 Jul;18(7):1128-35.

56. Ballen KK, Woolfrey AE, Zhu X, Ahn KW, Wirk B, Arora M, George B, Savani BN, Bolwell B, Porter DL, Copelan E, Hale G, Schouten HC, Lewis I, Cahn JY, Halter J, Cortes J, Kalaycio ME, Antin J, Aljurf MD, Carabasi MH, Hamadani M, McCarthy P, Pavletic S, Gupta V, Deeg HJ, Maziarz RT, Horowitz MM, Saber W. Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. Biol Blood Marrow Transplant. 2012 Sep;18(9):1446-54. PMCID: PMC3499973

57. Ross AL, Slain D, Cumpston A, Bryant AM, Hamadani M, Craig M. Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis. Int J Antimicrob Agents. 2012 Dec;40(6):557-61.

58. Sweet MA, Cumpston A, Briggs F, Craig M, Hamadani M. Impact of alcohol-impregnated port protectors and needleless neutral pressure connectors on central line-associated bloodstream infections and contamination of blood cultures in an inpatient oncology unit. Am J Infect Control. 2012 Dec;40(10):931-4.

59. Kharfan-Dabaja MA, Hamadani M, Reljic T, Nishihori T, Bensinger W, Djulbegovic B, Kumar A. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol. 2013 Jan 04;6:2. PMCID: PMC3548722

60. Veltri L, Regier M, Cumpston A, Leadmon S, Tse W, Craig M, Hamadani M. Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin. Bone Marrow Res. 2013;2013:414959. PMCID: PMC3652129

61. Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL. Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013 Feb;19(2):173-9. PMCID: PMC3553321

62. Cumpston A, Craig M, Hamadani M, Abraham J, Hobbs GR, Sarwari AR. Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit. Transpl Infect Dis. 2013 Apr;15(2):142-9.

63. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013 Apr;19(4):625-31. PMCID: PMC3640440

64. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant. 2013 May;19(5):746-53. PMCID: PMC3650915

65. Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013 Jul;19(7):1006-12.

66. Kanate AS, Watkins K, Cumpston A, Craig M, Hamadani M. Salvage bone marrow harvest in patients failing plerixafor-based stem cell mobilization attempt: feasibility and autologous transplantation outcomes. Biol Blood Marrow Transplant. 2013 Jul;19(7):1133-5.

67. Hamadani M. Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant? Bone Marrow Transplant. 2013 Aug;48(8):1013-21.

68. Kharfan-Dabaja MA, Nishihori T, Otrock ZK, Haidar N, Mohty M, Hamadani M. Monoclonal antibodies in conditioning regimens for hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013 Sep;19(9):1288-300.

69. Hamadani M, Kanate AS Dawn of a new era: targeting the B-cell receptor signaling pathway to conquer B-cell lymphomas. Community Oncology. Hamadani M., Kanate AS.: “Dawn of a new era: targeting the B-cell receptor signaling pathway to conquer B-cell lymphomas.” Community Oncology. 2013 October;10(10):279-281

70. Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, Deremer D, Jillella A, Craig M, Hamadani M. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplant. 2013 Oct;48(10):1279-84.

71. Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. J Clin Apher. 2013 Oct;28(5):359-67.

72. Chaudhary L, Kharfan-Dabaja MA, Hari P, Hamadani M. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era? Bone Marrow Transplant. 2013 Nov;48(12):1489-96.

73. Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, Lancet JE, Fernandez HF, Djulbegovic B, Kumar A. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol. 2013 Nov;163(3):315-25.

74. Palla AR, Hamadani M. Rituximab maintenance versus retreatment in follicular lymphoma. Hematol Oncol. 2013 Dec;31(4):171-8.

75. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 05;122(24):3863-70. PMCID: PMC3854108

76. Hamadani M, Gibson LF, Remick SC, Wen S, Petros W, Tse W, Brundage KM, Vos JA, Cumpston A, Bunner P, Craig MD. Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. J Clin Oncol. 2013 Dec 10;31(35):4416-23. PMCID: PMC3842909

77. Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014 Jan;20(1):89-97. PMCID: PMC3886623

78. Hamadani M, Abu Kar SM, Usmani SZ, Savani BN, Ayala E, Kharfan-Dabaja MA. Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. Semin Hematol. 2014 Jan;51(1):73-86.

79. Truong Q, Shah N, Knestrick M, Curley B, Hu Y, Craig M, Hamadani M. Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):50-5.

80. Truong Q, Shah N, Knestrick M, Curley B, Hu Y, Craig M, Hamadani M. Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):50-5.

81. Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 2014 Feb 01;32(4):273-81. PMCID: PMC3897255

82. Hamadani M. Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simply in the eyes of the transplanter? Biol Blood Marrow Transplant. 2014 Mar;20(3):292-4.

83. Rauenzahn S, Truong Q, Cumpston A, Goff L, Leadmon S, Evans K, Zhang J, Wen S, Craig M, Hamadani M, Kanate AS. Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Mar;20(3):415-20. PMCID: PMC4557764

84. Truong Q, Veltri L, Kanate AS, Hu Y, Craig M, Hamadani M, Cumpston A. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients. Ann Hematol. 2014 Apr;93(4):677-82.

85. Kanate AS, Pasquini MC, Hari PN, Hamadani M. Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. World J Stem Cells. 2014 Apr 26;6(2):69-81. PMCID: PMC3999783

86. Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN. Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! Bone Marrow Transplant. 2014 May;49(5):599-606.

87. Duléry R, Mohty M, Duhamel A, Robin M, Beguin Y, Michallet M, Vigouroux S, Lioure B, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Daguindau E, Ceballos P, Clément L, Dauriac C, Maillard N, Legrand F, Cornillon J, Guillerm G, François S, Lapusan S, Chevallier P, Damaj G, Yakoub-Agha I. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2014 May;20(5):646-54.

88. Michaelis LC, Hamadani M, Hari PN. Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age. Expert Rev Hematol. 2014 Jun;7(3):321-4.

89. Hamadani M, Vos JA, Craig MD. Reply to S. Fuji et al. J Clin Oncol. 2014 Jun 10;32(17):1860-1.

90. Wirk B, Fenske TS, Hamadani M, Zhang MJ, Hu ZH, Akpek G, Aljurf MD, Armand P, Ayala E, Bachanova V, Bolwell B, Cairo MS, Cashen A, Chen YB, Costa LJ, Farhan S, Freytes CO, Gajewski JL, Gibson J, Hale GA, Holmberg LA, Hsu JW, Inwards DJ, Kamble RT, Maharaj D, Maziarz RT, Munker R, Nath R, Reddy NM, Reeder CB, Rizzieri DA, Sauter CS, Savani BN, Schouten HC, Sureda A, Vose JM, Waller EK, Wiernik PH, Gale RP, Burns LJ, Saber W. Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. Biol Blood Marrow Transplant. 2014 Jul;20(7):951-9. PMCID: PMC4060436

91. McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ. Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant. 2014 Jul;20(7):960-8. PMCID: PMC4057955

92. Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W, Alpdogan O, Cashen A, Dandoy C, Finke R, Gale R, Gibson J, Hsu JW, Janakiraman N, Laughlin MJ, Lill M, Cairo MS, Munker R, Rowlings PA, Schouten HC, Shea TC, Stiff PJ, Waller EK. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Nov;20(11):1729-36. PMCID: PMC4194275

93. Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014 Dec;15(13):1503-1512.

94. Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski W, Rizzo JD, Hari PN, Hamadani M. Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. Biol Blood Marrow Transplant. 2014 Dec;20(12):1926-31.

95. Hamadani M. Autologous hematopoietic cell transplantation: an update for clinicians. Ann Med. 2014 Dec;46(8):619-32.

96. Copelan EA, Avalos BR, Ahn KW, Zhu X, Gale RP, Grunwald MR, Hamadani M, Hamilton BK, Hale GA, Marks DI, Waller EK, Savani BN, Costa LJ, Ramanathan M, Cahn JY, Khoury HJ, Weisdorf DJ, Inamoto Y, Kamble RT, Schouten HC, Wirk B, Litzow MR, Aljurf MD, van Besien KW, Ustun C, Bolwell BJ, Bredeson CN, Fasan O, Ghosh N, Horowitz MM, Arora M, Szer J, Loren AW, Alyea EP, Cortes J, Maziarz RT, Kalaycio ME, Saber W. Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. Biol Blood Marrow Transplant. 2015 Mar;21(3):552-8. PMCID: PMC4329042

97. Dhakal B, Singavi A, Cohen EP, Dangal M, Palmer J, Dall A, D'Souza A, Hamadani M, Hari PN. Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes. Bone Marrow Transplant. 2015 Mar;50(3):449-51.

98. Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherrill B, Ruiz-Soto R, Kaye JA, Hamadani M. Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):199-207.

99. Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, Fenske T, Hari PN, Hamadani M. Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. Bone Marrow Transplant. 2015 Apr;50(4):610-2.

100. Cooper BW, Kindwall-Keller TL, Craig MD, Creger RJ, Hamadani M, Tse WW, Lazarus HM. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):428-432.e2. PMCID: PMC4484305

101. Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, Perales MA, Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN, American Society for Blood and Marrow Transplantation. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015 Jul;21(7):1155-66.

102. Inamoto Y, Shah NN, Savani BN, Shaw BE, Abraham AA, Ahmed IA, Akpek G, Atsuta Y, Baker KS, Basak GW, Bitan M, DeFilipp Z, Gregory TK, Greinix HT, Hamadani M, Hamilton BK, Hayashi RJ, Jacobsohn DA, Kamble RT, Kasow KA, Khera N, Lazarus HM, Malone AK, Lupo-Stanghellini MT, Margossian SP, Muffly LS, Norkin M, Ramanathan M, Salooja N, Schoemans H, Wingard JR, Wirk B, Wood WA, Yong A, Duncan CN, Flowers ME, Majhail NS. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Aug;50(8):1013-23. PMCID: PMC4989866

103. Goyal SD, Zhang MJ, Wang HL, Akpek G, Copelan EA, Freytes C, Gale RP, Hamadani M, Inamoto Y, Kamble RT, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Reshef R, Ritchie DS, Saber W, Savani BN, Seber A, Shea TC, Tallman MS, Wirk B, Bunjes DW, Devine SM, de Lima M, Weisdorf DJ, Uy GL. Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. Bone Marrow Transplant. 2015 Aug;50(8):1057-62. PMCID: PMC4527880

104. Cumpston A, Caddell R, Shillingburg A, Lu X, Wen S, Hamadani M, Craig M, Kanate AS. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. Antimicrob Agents Chemother. 2015 Aug;59(8):4424-8. PMCID: PMC4505228

105. Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cashen AF, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Ghosh N, Holmberg LA, Inwards DJ, Kanate AS, Lazarus HM, Malone AK, Munker R, Mussetti A, Norkin M, Prestidge TD, Rowe JM, Satwani P, Siddiqi T, Stiff PJ, William BM, Wirk B, Maloney DG, Smith SM, Sureda AM, Carreras J, Hamadani M, Center for International Blood and Marrow Transplant Research Lymphoma Working Committee. Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2015 Sep;21(9):1605-11. PMCID: PMC4558181

106. Epperla N, Fenske TS, Hari PN, Hamadani M. Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. World J Transplant. 2015 Sep 24;5(3):81-8. PMCID: PMC4580930

107. Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang MJ, Carreras J, Montoto S, Perales MA, Aljurf MD, Akpek G, Bredeson CN, Costa LJ, Dandoy C, Freytes CO, Fung HC, Gale RP, Gibson J, Hamadani M, Hayashi RJ, Inamoto Y, Inwards DJ, Lazarus HM, Maloney DG, Martino R, Munker R, Nishihori T, Olsson RF, Rizzieri DA, Reshef R, Saad A, Savani BN, Schouten HC, Smith SM, Socié G, Wirk B, Yu LC, Saber W. The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. Biol Blood Marrow Transplant. 2015 Oct;21(10):1746-53. PMCID: PMC4568162

108. Hamadani M, Balasubramanian S, Hari PN. Ibrutinib in Refractory Classic Hodgkin's Lymphoma. N Engl J Med. 2015 Oct;373(14):1381-2.

109. Epperla N, Fenske TS, Lazarus HM, Hamadani M. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? Bone Marrow Transplant. 2015 Nov;50(11):1393-404.

110. Satwani P, Ahn KW, Carreras J, Abdel-Azim H, Cairo MS, Cashen A, Chen AI, Cohen JB, Costa LJ, Dandoy C, Fenske TS, Freytes CO, Ganguly S, Gale RP, Ghosh N, Hertzberg MS, Hayashi RJ, Kamble RT, Kanate AS, Keating A, Kharfan-Dabaja MA, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Prestidge TD, Rolon JM, Savani BN, Vose JM, Wood WA, Inwards DJ, Bachanova V, Smith SM, Maloney DG, Sureda A, Hamadani M. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant. 2015 Nov;50(11):1416-23. PMCID: PMC4633349

111. Hussain AS, Hari P, Brazauskas R, Arce-Lara C, Pasquini M, Hamadani M, D'Souza A. Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. Am J Hematol. 2015 Nov;90(11):E212-3. PMCID: PMC4618044

112. Veltri L, Cumpston A, Shillingburg A, Wen S, Luo J, Leadmon S, Watkins K, Craig M, Hamadani M, Kanate AS. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use. Cytotherapy. 2015 Dec;17(12):1785-92. PMCID: PMC4700501

113. Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. Biol Blood Marrow Transplant. 2015 Dec;21(12):2091-2099. PMCID: PMC4639453

114. Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Dec;50(12):1513-8. PMCID: PMC4548821

115. Nishihori T, Al-Kadhimi Z, Hamadani M, Kharfan-Dabaja MA. Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. Immunotherapy. 2016;8(4):435-47.

116. Turner RB, Cumpston A, Sweet M, Briggs F, Slain D, Wen S, Craig M, Hamadani M, Petros W. Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. Antimicrob Agents Chemother. 2016 Jan 11;60(3):1830-3. PMCID: PMC4775958

117. Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger NM, Hari PN, Ku GH, Ayala E, Chen AI, Chen YB, Cohen JB, Freytes CO, Gale RP, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Martino R, Mussetti A, Savani BN, Schouten HC, Usmani SZ, Wiernik PH, Wirk B, Smith SM, Sureda A, Hamadani M. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. Bone Marrow Transplant. 2016 Jan;51(1):58-66. PMCID: PMC4703480

118. Nelson AA, Harrington AM, Kroft S, Dahar MA, Hamadani M, Dhakal B. Presentation and management of post-allogeneic transplantation EBV-positive mucocutaneous ulcer. Bone Marrow Transplant. 2016 Feb;51(2):300-2.

119. Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, Fenske TS, Freytes C, Gale RP, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus HM, Olsson R, Perales MA, Rezvani A, Riches M, Saad A, Slavin S, Smith SM, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolaños-Meade J, Hamadani M. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016 Feb 18;127(7):938-47. PMCID: PMC4760094

120. Kharfan-Dabaja MA, El-Asmar J, Awan FT, Hamadani M, Ayala E. Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. Best Pract Res Clin Haematol. 2016 Mar;29(1):54-66.

121. Seftel MD, Neuberg D, Zhang MJ, Wang HL, Ballen KK, Bergeron J, Couban S, Freytes CO, Hamadani M, Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Paulson K, Saber W, Sallan SE, Soiffer R, Tallman MS, Woolfrey AE, DeAngelo DJ, Weisdorf DJ, Acute Leukemia Committee of the CIBMTR and the Dana Farber ALL Consortium. Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Am J Hematol. 2016 Mar;91(3):322-9. PMCID: PMC4764423

122. El-Asmar J, Reljic T, Ayala E, Hamadani M, Nishihori T, Kumar A, Kharfan-Dabaja MA. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis. Biol Blood Marrow Transplant. 2016 May;22(5):802-14.

123. Chaudhury S, Sparapani R, Hu ZH, Nishihori T, Abdel-Azim H, Malone A, Olsson R, Hamadani M, Daly A, Bacher U, Wirk BM, Kamble RT, Gale RP, Wood WA, Hale G, Wiernik PH, Hashmi SK, Marks D, Ustun C, Munker R, Savani BN, Alyea E, Popat U, Sobecks R, Kalaycio M, Maziarz R, Hijiya N, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. Biol Blood Marrow Transplant. 2016 Jun;22(6):1056-1064. PMCID: PMC4877686

124. Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, Hamadani M, Hari PN. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):379-86.

125. Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda A, Smith SM, Hamadani M. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016 Jul;174(2):235-48. PMCID: PMC4940282

126. DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y, Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Paplham P, Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM, Wood WA, Battiwalla M, Flowers MED, Savani BN, Shaw BE, CIBMTR Late Effects and Quality of Life Working Committee, EBMT Complications and Quality of Life Working Party. Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. Biol Blood Marrow Transplant. 2016 Aug;22(8):1493-1503. PMCID: PMC4949101

127. Fenske TS, Hamadani M, Cohen JB, Costa LJ, Kahl BS, Evens AM, Hamlin PA, Lazarus HM, Petersdorf E, Bredeson C. Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. Biol Blood Marrow Transplant. 2016 Sep;22(9):1543-1551. PMCID: PMC4981559

128. Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. J Clin Oncol. 2016 Sep 10;34(26):3141-9. PMCID: PMC5012706

129. Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherril B, Ruiz-Soto R, Kaye JA, Hamadani M. Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis. J Oncol Pharm Pract. 2016 Oct;22(5):666-78.

130. Dhakal B, Veltri LW, Fenske TS, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Esselman J, Watkins K, Pasquini MC, D'Souza A, Hari P, Kanate AS, Hamadani M. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2016 Oct;22(10):1773-1780.

131. Snyder M, Shillingburg A, Newton M, Hamadani M, Kanate AS, Craig M, Cumpston A. Impact of intravenous magnesium infusion rate during ambulatory replacements on serum magnesium concentrations after allogeneic stem cell transplant. Support Care Cancer. 2016 Oct;24(10):4237-40.

132. Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Cahn JY, Camitta B, Chen YB, Cutler CS, Gale RP, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus HM, Liesveld J, Litzow MR, Marks DI, Nishihori T, Olsson RF, Reshef R, Rowe JM, Saad AA, Sabloff M, Schouten HC, Shea TC, Soiffer RJ, Uy GL, Waller EK, Wiernik PH, Wirk B, Woolfrey AE, Bunjes D, Devine S, de Lima M, Sandmaier BM, Weisdorf D, Khoury HJ, Saber W. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016 Oct;122(19):3005-3014. PMCID: PMC5030151

133. Kharfan-Dabaja MA, Reljic T, El-Asmar J, Nishihori T, Ayala E, Hamadani M, Kumar A. Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. Future Oncol. 2016 Nov;12(22):2631-2642.

134. Epperla N, Shah N, Hamadani M, Richardson K, Kapke JT, Patel A, Teegavarapu SP, Carrum G, Hari PN, Pingali SR, Karmali R, Fenske TS. Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2016 Dec;16(12):672-678.

135. Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2016 Dec;22(12):2117-2125. PMCID: PMC5116249

136. Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani M. Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. Bone Marrow Transplant. 2016 Dec;51(12):1602-1604.

137. Epperla N, Olteanu H, Hamadani M. Think outside the box: Acanthamoeba encephalitis following autologous haematopoietic stem cell transplantation. Br J Haematol. 2016 Dec;175(5):758.

138. Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P. Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. Biol Blood Marrow Transplant. 2017 Jan;23(1):60-66. PMCID: PMC5182098

139. Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S, Bartz K, Raj RV, Hari PN, Hamadani M. Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. Bone Marrow Transplant. 2017 Jan;52(1):147-150.

140. Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Feb;23(2):269-277. PMCID: PMC5346183

141. DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y, Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Paplham P, Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM, Wood WA, Battiwalla M, Flowers ME, Savani BN, Shaw BE. Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. Bone Marrow Transplant. 2017 Feb;52(2):173-182. PMCID: PMC5288134

142. Shah N, Rauenzahn S, Veltri L, Wen S, Craig M, Hamadani M, Kanate AS, Cumpston A. Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL). Bone Marrow Transplant. 2017 Feb;52(2):321-322.

143. Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M. Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. Am J Hematol. 2017 Feb;92(2):161-170. PMCID: PMC5549936

144. Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, Pasquini M, D'Souza A, Hari P. Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):165-172.

145. Guru Murthy GS, Hamadani M, Bhatt VR, Dhakal I, Mehta P. Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival. Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):201-206.

146. Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017 Apr 10;35(11):1154-1161. PMCID: PMC5455603

147. Epperla N, Hamadani M, Fenske TS, Costa LJ. Incidence and survival trends in mantle cell lymphoma. Br J Haematol. 2018 Jun;181(5):703-706.

148. Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M. Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. Clin Lymphoma Myeloma Leuk. 2017 May;17(5):305-311.e2.

149. Liu HD, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald MR, Sabloff M, Olsson RF, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, Gerds A, Malone A, Tallman M, Reshef R, Marks DI, Copelan E, Gergis U, Savoie ML, Ustun C, Litzow MR, Cahn JY, Kindwall-Keller T, Akpek G, Savani BN, Aljurf M, Rowe JM, Wiernik PH, Hsu JW, Cortes J, Kalaycio M, Maziarz R, Sobecks R, Popat U, Alyea E, Saber W. Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. 2017 May;23(5):767-775. PMCID: PMC5590102

150. Hamadani M, Kanate AS, DiGilio A, Ahn KW, Smith SM, Lee JW, Ayala E, Chao N, Hari P, Bolaños-Meade J, Gress R, Smedegaard Anderson N, Chen YB, Farooq U, Schiller G, Yared J, Sureda A, Fenske TS, Olteanu H. Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2017 May;23(5):853-856. PMCID: PMC5410937

151. Jethava Y, Guru Murthy GS, Hamadani M. Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment? Hematol Oncol Stem Cell Ther. 2017 Jun;10(2):47-56.

152. Weil E, Zook F, Oxencis C, Canadeo A, Urmanski A, Waggoner M, Eastwood D, Pasquini M, Hamadani M, Hari P. Evaluation of the Pharmacokinetics and Efficacy of a Busulfan Test Dose in Adult Patients Undergoing Myeloablative Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2017 Jun;23(6):952-957.

153. Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani M. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. J Hematol Oncol. 2017 Jun 12;10(1):117. PMCID: PMC5469142

154. Shillingburg A, Kanate AS, Hamadani M, Wen S, Craig M, Cumpston A. Treatment of severe mucositis pain with oral ketamine mouthwash. Support Care Cancer. 2017 Jul;25(7):2215-2219. PMCID: PMC5500907

155. Kapke JT, Epperla N, Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R, Fenske TS. Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2017 Jul;17(7):408-414.

156. Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017 Jul 13;130(2):221-228. PMCID: PMC5510790

157. Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2017 Aug;23(8):1295-1302.

158. Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, Fenske TS, Smith SM, Sureda A, Olteanu H, Hamadani M. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. Br J Haematol. 2018 Sep;182(6):916-920. PMCID: PMC5796874

159. Hammons L, Brazauskas R, Pasquini M, Hamadani M, Hari P, D'Souza A. Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. Hematol Oncol Stem Cell Ther. 2018 Jun;11(2):105-111.

160. D'Souza A, Zhang MJ, Huang J, Fei M, Pasquini M, Hamadani M, Hari P. Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014. Leukemia. 2017 Sep;31(9):1998-2000. PMCID: PMC5587375

161. Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B. Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. Am J Hematol. 2017 Sep;92(9):E563-E565.

162. Bashey A, Zhang MJ, McCurdy SR, St Martin A, Argall T, Anasetti C, Ciurea SO, Fasan O, Gaballa S, Hamadani M, Munshi P, Al Malki MM, Nakamura R, O'Donnell PV, Perales MA, Raj K, Romee R, Rowley S, Rocha V, Salit RB, Solh M, Soiffer RJ, Fuchs EJ, Eapen M. Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2017 Sep 10;35(26):3002-3009. PMCID: PMC5590802

163. Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN. Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. Am J Hematol. 2017 Oct;92(10):E610-E611.

164. Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Di Bacco A, van de Velde H, Richardson PG, Moreau P. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i>. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. Haematologica. 2017 Oct;102(10):1767-1775. PMCID: PMC5622861

165. Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017 Nov;23(11):1826-1838.

166. Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB. Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. Transfusion. 2017 Nov;57(11):2775-2781.

167. Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, Shaw BE, Shahir K, Banerjee A, Drobyski WR. Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. Biol Blood Marrow Transplant. 2017 Nov;23(11):1955-1960.

168. Kharfan-Dabaja MA, El-Jurdi N, Ayala E, Kanate AS, Savani BN, Hamadani M. Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas? Bone Marrow Transplant. 2017 Nov;52(11):1487-1494.

169. Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, Hamadani M, Ghosh N, Reeder CB, Barnett E, Bravo MC, Martin P. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017 Nov 02;10(1):171. PMCID: PMC5668956

170. Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evens AM, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer. 2017 Nov 15;123(22):4411-4418.

171. D'Souza A, Flynn K, Chhabra S, Dhakal B, Hamadani M, Jacobsen K, Pasquini M, Weihrauch D, Hari P. Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. Contemp Clin Trials Commun. 2017 Dec;8:33-38. PMCID: PMC5898504

172. Epperla N, Hamadani M. Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):277-284.

173. Hamadani M, Horowitz MM. Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All? J Oncol Pract. 2017 Dec;13(12):798-806. PMCID: PMC5728364

174. Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. Hematol Oncol. 2017 Dec;35(4):528-535.

175. Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Br J Haematol. 2017 Dec;179(5):781-789.

176. Epperla N, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN, Fenske TS, Sureda A, Smith SM, Hamadani M. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biol Blood Marrow Transplant. 2018 Jan;24(1):78-85. PMCID: PMC5743624

177. Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018 Feb;180(4):534-544.

178. Kelly DL, Buchbinder D, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick A, Wirk BM, Yi J, Battiwalla M, Flowers ME, Savani B, Shaw BE. Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018 Feb;24(2):228-241. PMCID: PMC5768142

179. McCurdy SR, Zhang MJ, St Martin A, Al Malki MM, Bashey A, Gaballa S, Keesler DA, Hamadani M, Norkin M, Perales MA, Reshef R, Rocha V, Romee R, Solh M, Urbano-Ispizua A, Waller EK, Fuchs EJ, Eapen M. Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Adv. 2018 Feb 13;2(3):299-307. PMCID: PMC5812334

180. Myers RM, Hill BT, Shaw BE, Kim S, Millard HR, Battiwalla M, Majhail NS, Buchbinder D, Lazarus HM, Savani BN, Flowers MED, D'Souza A, Ehrhardt MJ, Langston A, Yared JA, Hayashi RJ, Daly A, Olsson RF, Inamoto Y, Malone AK, DeFilipp Z, Margossian SP, Warwick AB, Jaglowski S, Beitinjaneh A, Fung H, Kasow KA, Marks DI, Reynolds J, Stockerl-Goldstein K, Wirk B, Wood WA, Hamadani M, Satwani P. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer. 2018 Feb 15;124(4):816-825. PMCID: PMC5871233

181. Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. Biol Blood Marrow Transplant. 2018 Mar;24(3):478-485. PMCID: PMC5826888

182. Kharfan-Dabaja MA, Raj R, Nikolaenko L, Ahmed S, Reddy N, Nathan S, Cherry M, El-Jurdi N, Obiozor C, Fenske TS, Song J, Muzzafar T, Ayala E, Savani B, Khawandanah M, Caimi PF, Hamadani M, Forman SJ, Hussaini M, de Lima M, Olteanu H, Shah B, Chavez JC, Al Malki M, Kumar A, Ganguly S. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. Biol Blood Marrow Transplant. 2018 Mar;24(3):486-493.

183. Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Mar 01;4(3):343-350. PMCID: PMC5885822

184. Shah NN, Fenske TS, Hamadani M, Svoboda J. What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et al. Br J Haematol. 2019 Mar;184(5):838-840.

185. Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Lancet Haematol. 2018 Apr;5(4):e170-e180. PMCID: PMC7029813

186. Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-<i>versus</i>-host disease: low incidence of lower gastrointestinal tract disease. Haematologica. 2018 Apr;103(4):717-727. PMCID: PMC5865423

187. Sureda A, Zhang MJ, Dreger P, Carreras J, Fenske T, Finel H, Schouten H, Montoto S, Robinson S, Smith SM, Boumedil A, Hamadani M, Pasquini MC. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018 Apr 15;124(8):1733-1742. PMCID: PMC5946312

188. Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaños-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, Hamadani M. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Adv. 2018 Apr 24;2(8):933-940. PMCID: PMC5916010

189. Epperla N, Hamadani M, Ahn KW, He F, Kodali D, Kleman A, Hari PN, Pasquini M, Fenske TS, Craig MD, Kanate AS, Bachanova V. Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 May;24(5):983-988.

190. Buchbinder D, Kelly DL, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick AB, Wirk BM, Yi J, Battiwalla M, Flowers MDE, Savani B, Shaw BE. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplant. 2018 May;53(5):535-555. PMCID: PMC5985976

191. Rezahosseini O, Hanaei S, Hamadani M, Keshavarz-Fathi M, Rezaei N. The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma. Int Rev Immunol. 2018 May 04;37(3):165-173.

192. Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, Horowitz MM, Stolley MR, Sloan EK, Giles KE, Costanzo ES, Hamadani M, Chhabra S, Dhakal B, Rizzo JD. Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. BMC Cancer. 2018 May 24;18(1):593. PMCID: PMC5968588

193. Hashmi SK, Lee SJ, Savani BN, Burns L, Wingard JR, Perales MA, Palmer J, Chow E, Meyer E, Marks D, Mohty M, Inamoto Y, Rodriguez C, Nagler A, Sauter C, Komanduri KV, Pidala J, Hamadani M, Johnston L, Shah N, Shaughnessy P, Hamilton BK, Majhail N, Kharfan-Dabaja MA, Schriber J, DeFilipp Z, Tarlock KG, Fanning S, Curtin P, Rizzo JD, Carpenter PA. ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. Biol Blood Marrow Transplant. 2018 Jun;24(6):1119-1124.

194. Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf M, Chen AI, Choe H, Cohen J, Copelan E, Farooq U, Fenske TS, Freytes C, Gaballa S, Ganguly S, Jethava Y, Kamble RT, Kenkre VP, Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, Shah GL, Shah N, Solh M, Sureda A, William B, Cumpston A, Zelenetz AD, Link BK, Hamadani M. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2018 Jun;24(6):1163-1171. PMCID: PMC5993598

195. Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, Blum KA, Grover NS, Mathews SP, Gordon MJ, Danilov AV, Epperla N, Fenske TS, Hamadani M, Park SI, Flowers CR, Cohen JB. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer. 2018 Jun 01;124(11):2306-2315. PMCID: PMC5992038

196. Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer. 2018 Jun 15;124(12):2541-2551. PMCID: PMC5990449

197. Costa LJ, Landau HJ, Chhabra S, Hari P, Innis-Shelton R, Godby KN, Hamadani M, Tamari R, Anderton K, Dixon P, Giralt SA. Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Biol Blood Marrow Transplant. 2018 Jul;24(7):1379-1385. PMCID: PMC7590532

198. Dhakal B, D'Souza A, Lakshman A, Hamadani M, Chhabra S, Thompson R, Shah N, Pasquini M, Hari P. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 Aug;24(8):1610-1614.

199. Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. Biol Blood Marrow Transplant. 2018 Aug;24(8):1664-1670.

200. Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E. Incidence and survival of therapy related myeloid neoplasm in United States. Leuk Res. 2018 Aug;71:95-99.

201. Sureda A, Montoto S, Dreger P, Hamadani M, Pasquini MC. Reply to the persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular iymphoma. Cancer. 2018 Aug;124(16):3455-3456.

202. Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Bone Marrow Transplant. 2018 Sep;53(9):1210-1213.

203. Hashmi H, Hamadani M, Awan FT. Choosing the appropriate salvage therapy for B-cell non-Hodgkin lymphoma. Expert Opin Pharmacother. 2018 Oct;19(15):1631-1634.

204. Hamadani M. Advances in Transplantation for Lymphomas Resulting from CIBMTR Lymphoma Working Committee's Research Portfolio: A Five-Year Report (2013-2018). Adv Cell Gene Ther. 2018 Nov;1(3). PMCID: PMC7946113

205. Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A, Buchbinder D, Cahn JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayashi RJ, Hematti P, Inamoto Y, Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI, Olsson RF, Seo S, Steinberg A, William BM, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H, Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, Mahindra A, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, Litzow MR, Gale RP, Hashmi SK. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018 Nov;74:130-136. PMCID: PMC6219911

206. Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, Epperla N, Fenske TS, Hamadani M, Flowers CR, Cohen JB. Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. Leuk Lymphoma. 2018 Dec;59(12):2862-2870. PMCID: PMC6360945

207. Voshtina E, Szabo A, Hamadani M, Fenske TS, D'Souza A, Chhabra S, Saber W, Drobyski WR, Hari P, Shah NN. Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. Biol Blood Marrow Transplant. 2019 Jan;25(1):e33-e38.

208. Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019 Jan 10;12(1):6. PMCID: PMC6329157

209. Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, Esan O, Yang DT, Mato AR, Kanate AS, Olteanu H, Hamadani M, Fenske TS, Kenkre VP, Svoboda J, Cashen AF, Epperla N. Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.

210. Dreger P, Sureda A, Ahn KW, Eapen M, Litovich C, Finel H, Boumendil A, Gopal A, Herrera AF, Schmid C, Diez-Martin JL, Fuchs E, Bolaños-Meade J, Gooptu M, Al Malki MM, Castagna L, Ciurea SO, Dominietto A, Blaise D, Ciceri F, Tischer J, Corradini P, Montoto S, Robinson S, Gülbas Z, Hamadani M. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Adv. 2019 Feb 12;3(3):360-369. PMCID: PMC6373757

211. Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, Litzow MR, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz MM, Shaw BE, Miller JP, Hosoba S, Waller EK, Devine SM. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. Blood Adv. 2019 Mar 26;3(6):875-883. PMCID: PMC6436017

212. Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biol Blood Marrow Transplant. 2019 Apr;25(4):827-833.

213. Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ. Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. Leuk Lymphoma. 2019 Apr;60(4):940-946.

214. Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, Bredeson C, Fenske TS, Smith SM, Sureda A, Moskowitz A, Friedberg JW, Inwards DJ, Herrera AF, Kharfan-Dabaja MA, Reddy N, Montoto S, Robinson SP, Abutalib SA, Gisselbrecht C, Vose J, Gopal A, Shadman M, Perales MA, Carpenter P, Savani BN, Hamadani M. Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. JAMA Oncol. 2019 May 01;5(5):715-722. PMCID: PMC6988125

215. Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen AF, Fenske TS. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Adv. 2019 Jun 11;3(11):1661-1669. PMCID: PMC6560348

216. Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bolaños-Meade J, Byrne M, Cahn JY, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz MA, Farhadfar N, Gale RP, Ganguly S, Grunwald MR, Hahn T, Hashmi S, Hildebrandt GC, Holland HK, Hossain N, Kanakry CG, Kharfan-Dabaja MA, Khera N, Koc Y, Lazarus HM, Lee JW, Maertens J, Martino R, McGuirk J, Munker R, Murthy HS, Nakamura R, Nathan S, Nishihori T, Palmisiano N, Patel S, Pidala J, Olin R, Olsson RF, Oran B, Ringden O, Rizzieri D, Rowe J, Savoie ML, Schultz KR, Seo S, Shaffer BC, Singh A, Solh M, Stockerl-Goldstein K, Verdonck LF, Wagner J, Waller EK, De Lima M, Sandmaier BM, Litzow M, Weisdorf D, Romee R, Saber W. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019 Jun 25;3(12):1826-1836. PMCID: PMC6595262

217. Kanate AS, Szabo A, Raj RV, Bower K, Grulke R, Shah N, Ross KG, Cumpston A, Craig M, Pasquini MC, Shah N, Hari P, Hamadani M, Chhabra S. Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2019 Jul;25(7):1456-1464.

218. Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia. 2019 Jul;33(7):1736-1746. PMCID: PMC6755968

219. Kumar A, Reljic T, Hamadani M, Mohty M, Kharfan-Dabaja MA. Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplant. 2019 Jul;54(7):1094-1106.

220. Levis MJ, Chen YB, Hamadani M, Horowitz MM, Jones RJ, Blood and Marrow Transplant Clinical Trials Network. FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical? J Clin Oncol. 2019 Jul 01;37(19):1604-1607. PMCID: PMC6804888

221. Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M. Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. JAMA Netw Open. 2019 Jul 03;2(7):e196476.

222. Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P. Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019 Jul 29;9(8):56. PMCID: PMC6663939

223. D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A. A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2019 Aug;25(8):1492-1497.

224. Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 Aug;25(8):1689-1694.

225. Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res. 2019 Aug 15;25(16):5143-5155. PMCID: PMC6697588

226. Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, Bacher VU, Bejanyan N, Cohen JB, Farooq U, Fuchs EJ, Bolaños-Meade J, Ghosh N, Herrera AF, Hossain NM, Inwards D, Kanate AS, Martino R, Munshi PN, Murthy H, Mussetti A, Nieto Y, Perales MA, Romee R, Savani BN, Seo S, Wirk B, Yared JA, Sureda A, Fenske TS, Hamadani M. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2019 Sep;25(9):1859-1868. PMCID: PMC6755039

227. Meybodi MA, Cao W, Luznik L, Bashey A, Zhang X, Romee R, Saber W, Hamadani M, Weisdorf DJ, Chu H, Rashidi A. HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Adv. 2019 Sep 10;3(17):2581-2585. PMCID: PMC6737418

228. Zhao JC, Arnall JR, Martin AL, Atrash S, Bhutani M, Voorhees P, Avalos B, Copelan E, Ghosh N, Hamadani M, Usmani S, Ford P. A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2019 Oct;25(10):e305-e309.

229. Solomon SR, St Martin A, Shah NN, Fatobene G, Al Malki MM, Ballen KK, Bashey A, Bejanyan N, Bolaños Meade J, Brunstein CG, DeFilipp Z, Champlin RE, Fuchs EJ, Hamadani M, Hematti P, Kanakry CG, McGuirk JP, McNiece IK, Ciurea SO, Pasquini MC, Rocha V, Romee R, Patel SS, Vasu S, Waller EK, Wingard JR, Zhang MJ, Eapen M. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. Blood Adv. 2019 Oct 08;3(19):2836-2844. PMCID: PMC6784523

230. Guru Murthy GS, Szabo A, Hamadani M, Fenske TS, Shah NN. Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database. Oncologist. 2019 Nov;24(11):1488-1495. PMCID: PMC6853108

231. Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019 Dec;25(12):2305-2321.

232. Aljurf M, Weisdorf D, Hashmi S, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas MF, Ahmed SO, Novitzky N, Srivastava A, Seber A, Solh HE, Ghavamzadeh A, Confer D, Kodera Y, Hildegard G, Szer J, Horowitz MM, Niederwieser D. Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. Biol Blood Marrow Transplant. 2019 Dec;25(12):2330-2337.

233. Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P, Jerkins JH, Shah NN, Shaw BE, D'Souza A. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. Amyloid. 2019 Dec;26(4):210-215.

234. Badar T, Dhakal B, Szabo A, Padmanabhan A, Johnson BD, Heidtke S, Esselmann J, Chhabra S, Hamadani M, Hari P, D'Souza A. An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. J Clin Apher. 2019 Dec;34(6):686-691. PMCID: PMC6957224

235. Kahl BS, Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, Feingold JM, Ardeshna KM, Solh M, Heffner LT, Ungar D, He S, Boni J, Havenith K, O'Connor OA. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Clin Cancer Res. 2019 Dec 01;25(23):6986-6994.

236. Epperla N, Hamadani M, Reljic T, Kharfan-Dabaja MA, Savani BN, Kumar A. Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis. Cancer. 2019 Dec 15;125(24):4417-4425.

237. Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M. Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer J. 2019 Dec 03;9(12):97. PMCID: PMC6890709

238. Abedin S, Hamadani M. Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. J Exp Pharmacol. 2020;12:549-557. PMCID: PMC7705269

239. Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML. Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood. 2020 Jan 09;135(2):97-107. PMCID: PMC6952830

240. Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, Saini N, Shah AR, Patel RD, Ahmed S, Shah NN, Cashen AF, Hamadani M, Fenske TS. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020 Jan 14;4(1):47-54. PMCID: PMC6960457

241. Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW. Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. Blood Adv. 2020 Feb 11;4(3):467-476. PMCID: PMC7013267

242. Aljurf M, Weisdorf D, Hashmi SK, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas M, Ahmed SO, Novitzky N, Srivastava A, Seber A, Elsolh H, Ghavamzadeh A, Confer D, Kodera Y, Greinix H, Szer J, Horowitz M, Niederwieser D. Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations. Hematol Oncol Stem Cell Ther. 2020 Mar;13(1):7-16.

243. DeFilipp Z, Ancheta R, Liu Y, Hu ZH, Gale RP, Snyder D, Schouten HC, Kalaycio M, Hildebrandt GC, Ustun C, Daly A, Ganguly S, Inamoto Y, Litzow M, Szer J, Savoie ML, Hossain N, Kharfan-Dabaja MA, Hamadani M, Reshef R, Bajel A, Schultz KR, Gadalla S, Gerds A, Liesveld J, Juckett MB, Kamble R, Hashmi S, Abdel-Azim H, Solh M, Bacher U, Lazarus H, Olsson R, Cahn JY, Grunwald MR, Savani BN, Yared J, Rowe JM, Cerny J, Chaudhri NA, Aljurf M, Beitinjaneh A, Seo S, Nishihori T, Hsu JW, Ramanathan M, Alyea E, Popat U, Sobecks R, Saber W. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2020 Mar;26(3):472-479. PMCID: PMC7358778

244. Dreger P, Fenske TS, Montoto S, Pasquini MC, Sureda A, Hamadani M, European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation? Biol Blood Marrow Transplant. 2020 Apr;26(4):e77-e85. PMCID: PMC7207150

245. Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. J Clin Oncol. 2020 Apr 20;38(12):1273-1283. PMCID: PMC7164487

246. Chhabra S, Jerkins JH, Conto JE, Zellner K, Shah NN, Hari PN, Hamadani M. Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. Leuk Lymphoma. 2020 Apr;61(4):869-874.

247. Kanate AS, Perales MA, Hamadani M. Eligibility Criteria for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. J Natl Compr Canc Netw. 2020 May;18(5):635-643.

248. Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. Biol Blood Marrow Transplant. 2020 May;26(5):893-901.

249. Abedin SM, Hamadani M. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease. Expert Opin Investig Drugs. 2020 May;29(5):423-427.

250. Fatobene G, Rocha V, St Martin A, Hamadani M, Robinson S, Bashey A, Boumendil A, Brunstein C, Castagna L, Dominietto A, Finel H, Chalandon Y, Kenzey C, Kharfan-Dabaja M, Labussière-Wallet H, Moraleda JM, Pastano R, Perales MA, El Ayoubi HR, Ruggeri A, Sureda A, Volt F, Yakoub-Agha I, Zhang MJ, Gluckman E, Montoto S, Eapen M. Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. J Clin Oncol. 2020 May 10;38(14):1518-1526. PMCID: PMC7213591

251. Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer. 2020 May 15;126(10):2279-2287. PMCID: PMC7190439

252. Rashidi A, Meybodi MA, Cao W, Chu H, Warlick ED, Devine S, Pasquini MC, Weisdorf DJ, Hamadani M. Myeloablative versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis. Biol Blood Marrow Transplant. 2020 Jun;26(6):e138-e141.

253. Hamadani M, Khanal M, Ahn KW, Litovich C, Chow VA, Eghtedar A, Karmali R, Winter A, Fenske TS, Sauter C, Kharfan-Dabaja MA, Awan FT. Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. Biol Blood Marrow Transplant. 2020 Jun;26(6):1099-1105. PMCID: PMC7255948

254. Dhakal B, Narra RK, Giri S, Szabo A, Smunt TL, Ghose S, Pathak LK, Aryal M, Hamadani M, Chhabra S, Janz S, D'Souza A, Hari PN. Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. Cancer. 2020 Jun 15;126(12):2791-2801.

255. Chhabra S, Szabo A, Glisch C, George G, Narra RK, Harrington A, Jerkins JH, D'Souza A, Dhakal B, Pasquini MC, Hamadani M, Hari PN. Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. Biol Blood Marrow Transplant. 2020 Jul;26(7):1288-1297.

256. Eapen M, Zhang MJ, Tang XY, Lee SJ, Fei MW, Wang HL, Hebert KM, Arora M, Chhabra S, Devine SM, Hamadani M, D'Souza A, Pasquini MC, Phelan R, Rizzo JD, Saber W, Shaw BE, Weisdorf DJ, Horowitz MM. Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. Biol Blood Marrow Transplant. 2020 Jul;26(7):e161-e166. PMCID: PMC7206419

257. Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, Giralt SA, LeMaistre CF, Marks DI, Omel JL, Orchard PJ, Palmer J, Saber W, Veys PA, Carpenter PA, Hamadani M. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020 Jul;26(7):1247-1256.

258. Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, D'Souza A, Milano F, Phelan R, Saber W, Shaw BE, Weisdorf D, Devine SM, Horowitz MM. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant. 2020 Jul;26(7):1312-1317. PMCID: PMC7194895

259. Badar T, Astle J, Kakar IK, Zellner K, Hari PN, Hamadani M. Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression. Br J Haematol. 2020 Jul;190(2):e98-e101.

260. Ghosh N, Ahmed S, Ahn KW, Khanal M, Litovich C, Aljurf M, Bacher VU, Bredeson C, Epperla N, Farhadfar N, Freytes CO, Ganguly S, Haverkos B, Inwards D, Kamble RT, Lazarus HM, Lekakis L, Murthy HS, Nishihori T, Ramakrishnan P, Rizzieri DA, Yared JA, Kharfan-Dabaja MA, Sureda A, Hamadani M. Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. JAMA Oncol. 2020 Jul 01;6(7):1011-1018. PMCID: PMC7273311

261. Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020 Jul 14;4(13):3180-3190. PMCID: PMC7362362

262. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2020 Aug;26(8):e177-e182. PMCID: PMC7404814

263. Dhakal B, Miller S, Rein L, Pathak LK, Gloria L, Szabo A, Giri S, Chhabra S, Hamadani M, Paner A, Padmanabhan A, Janz S, D'Souza A, Hari P. Trends in the use of therapeutic plasma exchange in multiple myeloma. J Clin Apher. 2020 Aug;35(4):307-315.

264. Ahmed S, Ghosh N, Ahn KW, Khanal M, Litovich C, Mussetti A, Chhabra S, Cairo M, Mei M, William B, Nathan S, Bejanyan N, Olsson RF, Dahi PB, van der Poel M, Steinberg A, Kanakry J, Cerny J, Farooq U, Seo S, Kharfan-Dabaja MA, Sureda A, Fenske TS, Hamadani M. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. Br J Haematol. 2020 Aug;190(4):573-582. PMCID: PMC7575614

265. Thapa B, Caimi PF, Ardeshna KM, Solh M, Carlo-Stella C, Kahl BS, Hamadani M. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv. 2020 Aug 25;4(16):3850-3852. PMCID: PMC7448593

266. Abid MB, Hamadani M, Szabo A, Hari PN, Graham MB, Frank MO, Collier WS, Abedin S, Jerkins JH, Pasquini MC, Runaas L, Shah NN, Chhabra S. Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. Biol Blood Marrow Transplant. 2020 Sep;26(9):1670-1678.

267. Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020 Oct;26(10):1569-1575.

268. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 Oct;26(10):1876-1885. PMCID: PMC7571859

269. Chhabra S, Thapa B, Szabo A, Konings S, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Johnson BD, Hari PN, Hamadani M. Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. Biol Blood Marrow Transplant. 2020 Nov;26(11):2011-2017.

270. Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Hamadani M, Hari PN, Chhabra S. Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. Biol Blood Marrow Transplant. 2020 Dec;26(12):2229-2236.

271. Hamadani M, Litovich C, Ahn KW. Allogeneic Transplant Conditioning Regimens for Patients With Non-Hodgkin Lymphoma-Reply. JAMA Oncol. 2020 Dec 01;6(12):1984.

272. Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, Wood WA, Brazauskas R, Lehmann L, Pasquini MC, Seber A, Lu PH, Atsuta Y, Riches M, Perales MA, Worel N, Okamoto S, Srivastava A, Chemaly RF, Cordonnier C, Dandoy CE, Wingard JR, Kharfan-Dabaja MA, Hamadani M, Majhail NS, Waghmare AA, Chao N, Kröger N, Shaw B, Mohty M, Niederwieser D, Greinix H, Hashmi SK, WBMT and the CIBMTR Health Services and International Studies Committee. Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020 Dec;26(12):2181-2189. PMCID: PMC7380217

273. Bal S, Costa LJ, Sauter C, Litovich C, Hamadani M. Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy. Transplant Cell Ther. 2021 Jan;27(1):55.e1-55.e7. PMCID: PMC7965782

274. Epperla N, Ahn KW, Khanal M, Litovich C, Ahmed S, Ghosh N, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M. Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. Transplant Cell Ther. 2021 Jan;27(1):58-66. PMCID: PMC7972998

275. Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, Ciurea SO, Holtzman NG, Ii GLP, Devine SM, Mannis G, Grunwald MR, Appelbaum F, Rodriguez C, El Chaer F, Shah N, Hashmi SK, Kharfan-Dabaja MA, DeFilipp Z, Aljurf M, AlShaibani A, Inamoto Y, Jain T, Majhail N, Perales MA, Mohty M, Hamadani M, Carpenter PA, Nagler A. Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Transplant Cell Ther. 2021 Jan;27(1):6-20.

276. Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Warlick ED, Pasquini MC, Scott BL, Horwitz ME, Deeg HJ, Hourigan CS. Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome. JCO Precis Oncol. 2021;5. PMCID: PMC8140814

277. Dhakal B, Hari PN, Usmani SZ, Hamadani M. Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. Bone Marrow Transplant. 2021 Jan;56(1):9-19.

278. Epperla N, Hamadani M. A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine. Curr Hematol Malig Rep. 2021 Feb;16(1):19-24.

279. Shah NN, Hamadani M. Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma? J Clin Oncol. 2021 Feb 10;39(5):487-498.

280. Alotaibi S, Hamadani M, Al-Mansour M, Aljurf M. Breast Implant-associated Anaplastic Large Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):e272-e276.

281. Abid MB, Chhabra S, Buchan B, Graham MB, Abedin S, Thapa B, D'Souza A, George B, Hamadani M. Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. Hematol Oncol Stem Cell Ther. 2021 Mar;14(1):65-70. PMCID: PMC7543702

282. Badar T, Johnson BD, Hamadani M. Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. Bone Marrow Transplant. 2021 Mar;56(3):683-685.

283. Shah NN, Ahn KW, Litovich C, He Y, Sauter C, Fenske TS, Hamadani M. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood. 2021 Mar 11;137(10):1416-1423. PMCID: PMC7955408

284. Al Somali Z, Hamadani M, Kharfan-Dabaja M, Sureda A, El Fakih R, Aljurf M. Enteropathy-Associated T cell Lymphoma. Curr Hematol Malig Rep. 2021 Apr;16(2):140-147.

285. Sharma A, Badawy SM, Suelzer EM, Murthy HS, Prasad P, Eissa H, Carpenter PA, Hamadani M, Labopin M, Schoemans H, Tichelli A, Phelan R, Hamilton BK, Buchbinder D, Im A, Hunter R, Brazauskas R, Burns LJ. Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee. Bone Marrow Transplant. 2021 Apr;56(4):786-797. PMCID: PMC8168056

286. Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M. Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer J. 2021 Apr 29;11(4):82. PMCID: PMC8085088

287. Yassine F, Sandoval-Sus J, Ayala E, Chavez J, Hamadani M, Kharfan-Dabaja MA. Cellular Therapies for Mantle Cell Lymphoma. Transplant Cell Ther. 2021 May;27(5):363-370.

288. Sharma A, Badawy SM, Suelzer EM, Murthy HS, Prasad P, Eissa H, Carpenter PA, Hamadani M, Labopin M, Schoemans H, Tichelli A, Phelan R, Hamilton BK, Buchbinder D, Im A, Hunter R, Brazauskas R, Burns LJ. Systematic Reviews in Hematopoietic Cell Transplantation and Cellular Therapy: Considerations and Guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and Center for International Blood and Marrow Transplant Research Late Effects and Quality of Life Working Committee. Transplant Cell Ther. 2021 May;27(5):380-388. PMCID: PMC8415092

289. Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O'Connor OA, Feingold JM, Ardeshna KM, Townsend W, Solh M, Heffner LT, Ungar D, Wang L, Boni J, Havenith K, Qin Y, Kahl BS. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645. PMCID: PMC8138546

290. Hamadani M, Collins GP, Caimi PF, Samaniego F, Spira A, Davies A, Radford J, Menne T, Karnad A, Zain JM, Fields P, Havenith K, Cruz HG, He S, Boni J, Feingold J, Wuerthner J, Horwitz S. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. Lancet Haematol. 2021 Jun;8(6):e433-e445. PMCID: PMC9241579

291. Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):790-800.

292. Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Soiffer RJ, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. Transplant Cell Ther. 2021 Jun;27(6):483.e1-483.e6. PMCID: PMC8217373

293. Sharma A, Badawy SM, Suelzer EM, Murthy HS, Prasad P, Eissa H, Carpenter PA, Hamadani M, Labopin M, Schoemans H, Tichelli A, Phelan R, Hamilton BK, Buchbinder D, Im A, Hunter R, Brazauskas R, Burns LJ. Correction: Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee. Bone Marrow Transplant. 2021 Jun;56(6):1486.

294. Jella TK, Cwalina TB, Treisman J, Hamadani M. Risk Factors for Cost-Related Delays to Medical Care Among Lymphoma Patients: A 22-Year Analysis of a Nationally Representative Sample. Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):e619-e625.

295. Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021 Jul;35(7):2076-2085. PMCID: PMC8257494

296. Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D. Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021 Jul;35(7):2140. PMCID: PMC8329698

297. Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS. Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncol. 2021 Jul 01;7(7):993-1003. PMCID: PMC8283558

298. Abboud R, Wan F, Mariotti J, Arango M, Castagna L, Romee R, Hamadani M, Chhabra S. Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis. Bone Marrow Transplant. 2021 Nov;56(11):2763-2770.

299. Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, Burroughs LM, Majhail N, Al-Homsi AS, Al-Kadhimi ZS, Bar M, Bertaina A, Boelens JJ, Champlin R, Chaudhury S, DeFilipp Z, Dholaria B, El-Jawahri A, Fanning S, Fraint E, Gergis U, Giralt S, Hamilton BK, Hashmi SK, Horn B, Inamoto Y, Jacobsohn DA, Jain T, Johnston L, Kanate AS, Kansagra A, Kassim A, Kean LS, Kitko CL, Knight-Perry J, Kurtzberg J, Liu H, MacMillan ML, Mahmoudjafari Z, Mielcarek M, Mohty M, Nagler A, Nemecek E, Olson TS, Oran B, Perales MA, Prockop SE, Pulsipher MA, Pusic I, Riches ML, Rodriguez C, Romee R, Rondon G, Saad A, Shah N, Shaw PJ, Shenoy S, Sierra J, Talano J, Verneris MR, Veys P, Wagner JE, Savani BN, Hamadani M, Carpenter PA. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021 Aug;27(8):642-649.

300. Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplant. 2021 Dec;56(12):2911-2921. PMCID: PMC8639670

301. Riedell PA, Hamadani M, Ahn KW, Litovich C, Murthy GSG, Locke FL, Brunstein CG, Merryman RW, Stiff PJ, Pawarode A, Nishihori T, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM. Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. Transplant Cell Ther. 2021 Nov;27(11):911.e1-911.e7. PMCID: PMC8556305

302. Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 Sep;35(9):2672-2683.

303. Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. Transplant Cell Ther. 2021 Sep;27(9):720-728. PMCID: PMC8447221

304. Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen JB. Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. Eur J Haematol. 2021 Sep;107(3):301-310. PMCID: PMC8338766

305. Herrera AF, Ahn KW, Litovich C, Chen Y, Assal A, Bashir Q, Bayer RL, Coleman M, DeFilipp Z, Farhadfar N, Greenwood M, Hahn T, Horwitz M, Jacobson C, Jaglowski S, Lachance S, Langston A, Mattar B, Maziarz RT, McGuirk J, Mian MAH, Nathan S, Phillips A, Rakszawski K, Sengeloev H, Shenoy S, Stuart R, Sauter CS, Kharfan-Dabaja MA, Hamadani M. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. Blood Adv. 2021 Sep 28;5(18):3528-3539. PMCID: PMC8945575

306. Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T, Longo W, Hari P, Hamadani M. Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):e775-e781.

307. Dhakal B, Abedin S, Fenske T, Chhabra S, Ledeboer N, Hari P, Hamadani M. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. Blood. 2021 Oct 07;138(14):1278-1281. PMCID: PMC8332674

308. Abedin S, Rashid N, Schroeder M, Romee R, Nauffal M, Alhaj Moustafa M, Kharfan-Dabaja MA, Palmer J, Hogan W, Hefazi M, Larson S, Holtan S, DeFilipp Z, Jayani R, Dholaria B, Pidala J, Khimani F, Grunwald MR, Butler C, Hamadani M. Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis. Br J Haematol. 2021 Nov;195(3):429-432. PMCID: PMC9293486

309. Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB. Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. Am J Hematol. 2021 Nov 01;96(11):1374-1384. PMCID: PMC8511300

310. Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB. Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. Am J Hematol. 2021 Nov 01;96(11):1374-1384. PMCID: PMC8511300

311. Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB. Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. Am J Hematol. 2021 Nov 01;96(11):1374-1384. PMCID: PMC8511300

312. Patel A, Murthy GSG, Hamadani M, Szabo A, Knight JM. The Impact of Beta-Blocker Use at the Time of Hematopoietic Cell Transplantation on the Development of Acute and Chronic Graft-Versus-Host Disease. Hematol Oncol Stem Cell Ther. 2023 Apr 04;16(3):209-216.

313. Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, Horowitz MM. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. Transplant Cell Ther. 2021 Nov;27(11):885-907. PMCID: PMC8556300

314. Ahmed N, Hamadani M. Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Expert Rev Anticancer Ther. 2021 Dec;21(12):1313-1320.

315. Zurko J, Hamadani M. Loncastuximab tesirine for diffuse large B-cell lymphoma. Drugs Today (Barc). 2021 Dec;57(12):733-743.

316. Epperla N, Hamadani M. Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors. Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):247-253. PMCID: PMC8791097

317. Riedell PA, Hamadani M, Ahn KW, Litovich C, Brunstein CG, Cashen AF, Cohen JB, Epperla N, Hill BT, Im A, Inwards DJ, Lister J, McCarty JM, Ravi Kiran Pingali S, Shadman M, Shaughnessy P, Solh M, Stiff PJ, Vose JM, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM. Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. Br J Haematol. 2021 Dec;195(5):757-763. PMCID: PMC8627449

318. Furqan F, Hamadani M. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data. Ther Adv Hematol. 2022;13:20406207221087511. PMCID: PMC8943462

319. Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Badar T, Guo J, Hamadani M, Fenske TS, Malecek MK, Kahl BS, Flowers CR, Blum KA, Cohen JB. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv. 2021 Dec 14;5(23):5179-5189. PMCID: PMC9153047

320. Ahmed G, Hamadani M, Shah NN. CAR T-cell therapy for secondary CNS DLBCL. Blood Adv. 2021 Dec 28;5(24):5626-5630. PMCID: PMC8714710

321. Iqbal M, Savani BN, Hamadani M. New Indications and platforms for CAR-T therapy in lymphomas beyond DLBCL. EJHaem. 2022 Jan;3(Suppl 1):11-23. PMCID: PMC8725814

322. Hamadani M, Gopal AK, Pasquini M, Kim S, Qiu X, Ahmed S, Lazaryan A, Bhatt VR, Daly A, Lulla P, Ciurea S, Gauthier J, Agrawal V, Grover NS, Lekakis L, Modi D, Dahi PB, Herr MM, Johnson PC, Hashmi H, Hematti P, Locke FL. Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Blood Adv. 2022 Jan 25;6(2):486-494. PMCID: PMC8791562

323. Ahmed S, Zhao Q, Hanel W, Qazilbash MH, Patel K, Narra R, Kansagra A, Iqbal M, Awan FT, Christian B, Jaglowski SM, Kharfan-Dabaja MA, Hamadani M, Epperla N. Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. Hematol Oncol. 2022 Feb;40(1):48-56.

324. Jella T, Cwalina TB, Hamadani M. Epidemiology of Food Insecurity in a Nationally Representative Sample of Lymphoma Patients. Clin Lymphoma Myeloma Leuk. 2022 Feb;22(2):e128-e134.

325. Meyers G, Hamadani M, Martens M, Ali H, Choe H, Dawson P, Harris AC, van Hooren E, Klaassen W, Leifer E, MacMillan ML, van Oosterhout Y, Perez L, Pusic I, Vo P, Levine JE. Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD. Bone Marrow Transplant. 2022 Feb;57(2):302-303. PMCID: PMC8825705

326. Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, Chen Y, Boumendil A, Zain J, Castagna L, Cashen AF, Blaise D, Shadman M, Pastano R, Khimani F, Arat M, Dietrich S, Schmitz N, Glass B, Kharfan-Dabaja MA, Corradini P, Sauter CS, Montoto S, Kwon M, Herrera AF, Dreger P. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. Blood Adv. 2022 Feb 08;6(3):920-930. PMCID: PMC8945300

327. Johnson AK, Lorimer EL, Szabo A, Wu R, Shah NN, D'Souza A, Chhabra S, Hamadani M, Dhakal B, Hari P, Rao S, Carlson K, Williams CL, Knight JM. Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol. Yale J Biol Med. 2022 Mar;95(1):45-56. PMCID: PMC8961707

328. Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F, Ganguly S, Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi PN, Beitinjaneh A, Reagan PM, Herrera AF, Sauter CS, Kharfan-Dabaja MA, Hamadani M. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022 Mar 03;139(9):1330-1339. PMCID: PMC8900276

329. Dhakal B, Chhabra S, Savani BN, Hamadani M. Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. Br J Haematol. 2022 Apr;197(1):28-40.

330. Savani M, Ahn KW, Chen Y, Ahmed S, Cashen AF, Shadman M, Modi D, Khimani F, Cutler CS, Zain J, Brammer JE, Rezvani AR, Fenske TS, Sauter CS, Kharfan-Dabaja MA, Herrera AF, Hamadani M. Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant. Br J Haematol. 2022 Apr;197(2):212-222. PMCID: PMC9018546

331. Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, Hamadani M. Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. Cancer Cell. 2022 Apr 11;40(4):340-342. PMCID: PMC8864440

332. Alseraihy A, McGrath E, Niederwieser D, Chabannon C, Szer J, Mohty M, Kharfan-Dabaja MA, Orchard K, Schwartz J, Rasheed W, Koh M, Kröger N, Kodera Y, Fakih RE, Worel N, Manson L, Rintala T, Tabakhi A, Savani B, Gergis U, Sureda A, Eldridge PW, Yakoub-Agha I, Hamadani M, Weisdorf D, Greinix H, Aljurf M. Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy. Transplant Cell Ther. 2022 Aug;28(8):455-462.

333. Derman BA, Belli AJ, Battiwalla M, Hamadani M, Kansagra A, Lazarus HM, Wang CK. Reality check: Real-world evidence to support therapeutic development in hematologic malignancies. Blood Rev. 2022 May;53:100913.

334. Zurko JC, Johnson BD, Aschenbrenner E, Fenske TS, Hamadani M, Hari P, Shah NN. Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. JAMA Oncol. 2022 May 01;8(5):773-775. PMCID: PMC8914887

335. Caimi PF, Ardeshna KM, Reid E, Ai W, Lunning M, Zain J, Solh M, Kahl BS, Hamadani M. The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy. Clin Lymphoma Myeloma Leuk. 2022 May;22(5):e335-e339.

336. Calabretta E, Hamadani M, Zinzani PL, Caimi P, Carlo-Stella C. The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma. Blood. 2022 Jul 28;140(4):303-308. PMCID: PMC9335500

337. Mei M, Hamadani M, Ahn KW, Chen Y, Kharfan-Dabaja MA, Sauter C, Herrera AF. Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit. Haematologica. 2022 May 01;107(5):1214-1217. PMCID: PMC9052914

338. Munshi PN, Chen Y, Ahn KW, Awan FT, Cashen A, Shouse G, Shadman M, Shaughnessy P, Zurko J, Locke FL, Goodman AM, Bisneto JCV, Sauter C, Kharfan-Dabaja MA, Meyers G, Jaglowski S, Herrera A, Hamadani M. Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. Transplant Cell Ther. 2022 Aug;28(8):487.e1-487.e7. PMCID: PMC9375438

339. AlYamany R, Kharfan-Dabaja MA, Hamadani M, Alshaibani A, Aljurf M. The Evolution of Our Understanding of Immunoproliferative Small Intestinal Disease (IPSID) over Time. Curr Oncol. 2022 May 23;29(5):3759-3769. PMCID: PMC9139652

340. Hamadani M, Liao L, Yang T, Chen L, Moskowitz C. Characteristics and Clinical Outcomes of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received At Least 3 Lines of Therapies. Clin Lymphoma Myeloma Leuk. 2022 Jun;22(6):373-381.

341. Ahmed N, Kumar A, Kharfan-Dabaja MA, DeFilipp Z, Herrera A, Hashmi S, Dholaria B, Perales MA, Carpenter PA, Hamadani M. ASTCT Committee on Practice Guidelines Survey on Evaluation &amp; Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy. Transplant Cell Ther. 2022 Sep;28(9):523-529.

342. Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, Cowan A, Poudyal BS, Costello C, Gay F, Cook G, Quach H, Einsele H, Schriber J, Hou J, Costa L, Aljurf M, Chaudhry M, Beksac M, Prince M, Mohty M, Janakiram M, Callander N, Biran N, Malhotra P, Otero PR, Moreau P, Abonour R, Iftikhar R, Silberman R, Mailankody S, Gregory T, Lin Y, Carpenter P, Hamadani M, Usmani S, Kumar S. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. Transplant Cell Ther. 2022 Jun;28(6):284-293.

343. Mohan M, Nagavally S, Shah N NN, Michaelis L, Chhabra S, Souza AD, Abedin S, Runaas L, Guru Murthy GS, Longo W, Hamadani M, Dhakal B, Hari P, Fenske TS. Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e495-e497. PMCID: PMC8767926

344. Ahmed N, Shahzad M, Shippey E, Bansal R, Mushtaq MU, Mahmoudjafari Z, Faisal MS, Hoffmann M, Abdallah AO, Divine C, Hamadani M, McGuirk J, Shune L. Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access. Transplant Cell Ther. 2022 Jul;28(7):358-364.

345. Phelan R, Chen M, Bupp C, Bolon YT, Broglie L, Brunner-Grady J, Burns LJ, Chhabra S, Christianson D, Cusatis R, Devine SM, D'Souza A, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini M, Pérez WS, Riches M, Rizzo D, Saber W, Spellman SR, Stefanski HE, Steinert P, Weisdorf D, Horowitz M, Auletta JJ, Shaw BE, Arora M. Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. Transplant Cell Ther. 2022 Jul;28(7):409.e1-409.e10. PMCID: PMC9840526

346. Hamadani M. Did brentuximab vedotin's rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results? Haematologica. 2022 Jul 01;107(7):1500-1502. PMCID: PMC9244808

347. Halahleh K, Al Rimawi D, Abu Ghosh A, Muradi I, Da'na W, Hamadani M. The Impact of Post-Hematopoietic Stem Cell Transplant Tyrosine Kinase Inhibitors in Philadelphia-Positive Acute Lymphoblastic Leukemia. Hematol Oncol Stem Cell Ther. 2022 Dec 23;15(4):219-222.

348. Hamadani M, Chen L, Song Y, Xu MK, Liao L, Caimi PF, Carlo-Stella C. Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e738-e744.

349. Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study. EClinicalMedicine. 2023 May;59:101983. PMCID: PMC10133891

350. Ahmed N, Mahmoudjafari Z, Hamadani M, Hashmi H. Bridging the Gap: Early Transition and Hybrid Models of Care to Improve Access to Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2023 Jun;29(6):399-402.

351. Auletta JJ, Kou J, Chen M, Bolon YT, Broglie L, Bupp C, Christianson D, Cusatis RN, Devine SM, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Perez WS, Phelan R, Riches ML, Rizzo JD, Saber W, Spellman SR, Stefanski HE, Steinert P, Tuschl E, Yusuf R, Zhang MJ, Shaw BE. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2023 Jun;29(6):346.e1-346.e10. PMCID: PMC10239334

352. Fraint E, Abdel-Azim H, Bhatt NS, Broglie L, Chattha A, Kohorst M, Ktena YP, Lee MA, Long S, Qayed M, Sharma A, Stefanski H, Vatsayan A, Wray L, Hamadani M, Carpenter PA. Evaluation of Children with Malignancies for Blood and Marrow Transplantation: A Report from the ASTCT Committee on Practice Guidelines. Transplant Cell Ther. 2023 May;29(5):293-301.

353. Dhakal B, Zhang MJ, Burns LJ, Tang X, Meyer C, Mau LW, Nooka AK, Stadtmauer E, Micallef IN, McGuirk J, Costa L, Juckett MB, Shah N, Champlin RE, Usmani SZ, Farag SS, Nishihori T, Roy V, Bodiford A, Barnes YJ, Drea EJ, Hari P, Hamadani M. Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. Haematologica. 2023 Aug 01;108(8):2249-2254. PMCID: PMC10388259

354. Mussetti A, Kanate AS, Wang T, He M, Hamadani M, Finel H Sr, Boumendil A Sr, Glass B, Castagna L, Dominietto A, McGuirk J, Blaise D, Gülbas Z, Diez-Martin J, Marsh SGE, Paczesny S, Gadalla SM, Dreger P, Zhang MJ, Spellman SR, Lee SJ, Bolon YT, Sureda A. Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas. Transplant Cell Ther. 2023 Mar;29(3):184.e1-184.e9. PMCID: PMC10316698

355. Sasu BJ, Opiteck GJ, Gopalakrishnan S, Kaimal V, Furmanak T, Huang D, Goswami A, He Y, Chen J, Nguyen A, Balakumaran A, Shah NN, Hamadani M, Bone KM, Prashad S, Bowen MA, Pertel T, Embree HD, Gidwani SG, Chang D, Moore A, Leonard M, Amado RG. Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells. Mol Ther. 2023 Mar 01;31(3):676-685. PMCID: PMC10014221

356. Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, Fenske TS, Martin P, Malecek MK, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, Hsi ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv. 2023 Jun 13;7(11):2287-2296. PMCID: PMC10225877

357. DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, Brunner AM, Dholaria B, Walker AR, Kröger N, Bejanyan N, Atallah E, Tamari R, Solh MM, Percival ME, de Lima M, Scott B, Oran B, Garcia-Manero G, Hamadani M, Carpenter P, DeZern AE. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. Transplant Cell Ther. 2023 Feb;29(2):71-81.

358. Furqan F, Maring M, Szabo A, Fenske TS, Hamadani M, Shah NN. Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy. Blood Adv. 2023 Jun 13;7(11):2463-2467. PMCID: PMC10241849

359. Kuruvilla J, Armand P, Hamadani M, Kline J, Moskowitz CH, Avigan D, Brody JD, Ribrag V, Herrera AF, Morschhauser F, Kanate A, Zinzani PL, Bitran J, Ghesquieres H, Schuster SJ, Farooqui M, Marinello P, Bartlett NL. Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study. Leuk Lymphoma. 2023 Jan;64(1):130-139.

360. Toukam M, Wuerthner J, Havenith K, Hamadani M, Caimi PF, Kopotsha T, Cruz HG, Boni JP. Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2023 Jan;91(1):13-24.

361. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885]. Transplant Cell Ther. 2022 Oct;28(10):717.

362. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM. Corrigendum to 'Current Use and Trends in Hematopoietic Cell Transplantation in the United States' [Transplantation and Cellular Therapy 26/8 (2020) e177-e182]. Transplant Cell Ther. 2022 Oct;28(10):715-716.

363. Furqan F, Ahn KW, Chen Y, Kaur M, Abutalib SA, Ahmed N, Ahmed S, Kharfan-Dabaja MA, Friedberg J, Gregory T, Hill L, Sterling C, Barta SK, Shadman M, Perales MA, Zain J, Herrera AF, Sauter C, Hamadani M. Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma. Br J Haematol. 2023 Jan;200(1):54-63. PMCID: PMC9772096

364. Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D, Samanas L, Fei T, Armijo G, Abedin S, Longo W, Hari P, Hamadani M, Shah NN, Runaas L, Jerkins JH, Van den Brink M, Peled JU, Drobyski WR. Mitigation of gastrointestinal graft-<i>versus</i>-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. Haematologica. 2023 Jan 01;108(1):250-256. PMCID: PMC9827178

365. Zurko JC, Fenske TS, Johnson BD, Bucklan D, Szabo A, Xu H, Chaney K, Hamadani M, Hari P, Shah NN. Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells. Am J Hematol. 2022 Dec;97(12):1580-1588.

366. Ahmed G, Bhasin-Chhabra B, Szabo A, Shah NN, Longo W, Dhakal B, Chhabra S, D'Souza A, Fenske TS, Hamadani M. Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):863-868.

367. Toukam M, Boni JP, Hamadani M, Caimi PF, Cruz HG, Wuerthner J. Exposure-response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2023 Jan;91(1):1-12.

368. Epperla N, Reljic T, Chowdhury SM, Ferreri AJM, Kumar A, Hamadani M. Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis. Hematol Oncol. 2023 Feb;41(1):88-96.

369. Muhsen IN, El Fakih R, Hamadani M, Lazarus HM, Kharfan-Dabaja MA, Aljurf M. Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell Lymphomas. Clin Hematol Int. 2022 Jun;4(1-2):1-10. PMCID: PMC9358781

370. Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022 Aug;23(8):1066-1077.

371. Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2023 Jan 01;108(1):98-109. PMCID: PMC9827150

372. Alderuccio JP, Ai WZ, Radford J, Solh M, Ardeshna KM, Lunning MA, Hess BT, Zinzani PL, Stathis A, Carlo-Stella C, Hamadani M, Kahl BS, Ungar D, Kilavuz T, Yu E, Qin Y, Caimi PF. Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Blood Adv. 2022 Aug 23;6(16):4736-4739. PMCID: PMC9631657

373. Perales MA, Anderson LD Jr, Jain T, Kenderian SS, Oluwole OO, Shah GL, Svoboda J, Hamadani M. Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2022 Sep;28(9):546-559. PMCID: PMC9427727

374. Meyers G, Hamadani M, Martens M, Ali H, Chevallier P, Choe H, Harris AC, Holler E, van Hooren E, Klaassen W, Leifer E, van Oosterhout Y, Perez L, Pusic I, Stelljes M, van der Velden W, Ammatuna E, Beauvais D, Cornillon J, Maziarz RT, Schetelig J, Romeril J, MacMillan ML, Levine JE, Socié G. Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002. Bone Marrow Transplant. 2023 Dec;58(12):1416-1418.

375. Gordon LI, Liu FF, Braverman J, Hoda D, Ghosh N, Hamadani M, Hildebrandt GC, Peng L, Guo S, Shi L, Sehgal A. Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study. Haematologica. 2024 Mar 01;109(3):857-866. PMCID: PMC10905070

376. Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica. 2024 Apr 01;109(4):1184-1193. PMCID: PMC10985439

377. Arshad S, Fang X, Ahn KW, Kaur M, Scordo M, Sauter CS, Furqan F, Awan FT, Hamadani M. Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning. Bone Marrow Transplant. 2023 Nov;58(11):1203-1208. PMCID: PMC11078515

378. Hamadani M, Coleman M, Boccia R, Duras J, Hutchings M, Zinzani PL, Cordoba R, Oreiro MB, Williams V, Liu H, Stouffs M, Langmuir P, Sancho JM. Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study. Hematol Oncol. 2023 Dec;41(5):848-857.

379. Kanate AS, Majhail N, DeFilipp Z, Dhakal B, Dholaria B, Hamilton B, Herrera AF, Inamoto Y, Jain T, Perales MA, Carpenter PA, Hamadani M. Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2023 Oct;29(10):594-597.

380. Epperla N, Kumar A, Abutalib SA, Awan FT, Chen YB, Gopal AK, Holter-Chakrabarty J, Kekre N, Lee CJ, Lekakis L, Lin Y, Mei M, Nathan S, Nastoupil L, Oluwole O, Phillips AA, Reid E, Rezvani AR, Trotman J, Zurko J, Kharfan-Dabaja MA, Sauter CS, Perales MA, Locke FL, Carpenter PA, Hamadani M. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2023 Sep;29(9):548-555.

381. Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG, BMT CTN 1703 Investigators. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med. 2023 Jun 22;388(25):2338-2348. PMCID: PMC10575613

382. Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, Hamadani M, D'Souza A, Hari P, Dhakal B. Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. Br J Haematol. 2024 Mar;204(3):887-891.

383. Kelkar AH, Cliff ERS, Jacobson CA, Abel GA, Dijk SW, Krijkamp EM, Redd R, Zurko JC, Hamadani M, Hunink MGM, Cutler C. Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis. Ann Intern Med. 2023 Dec;176(12):1625-1637.

384. Oluwole OO, Dholaria B, Knight TE, Jain T, Locke FL, Ramsdell L, Nikiforow S, Hashmi H, Mooney K, Bhaskar ST, Morris K, Gatwood K, Baer B, Anderson LD Jr, Hamadani M. Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2024 Feb;30(2):131-142.

385. Munoz J, Flinn IW, Cohen JB, Sachs J, Exter B, Ranger A, Harris P, Payumo F, Nath R, Hamadani M, Westin JR, Bachanova V. Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20⁺ B Cell Lymphoma. Transplant Cell Ther. 2024 Feb;30(2):241.e1-241.e8.

386. Alderuccio JP, Reis IM, Hamadani M, Nachiappan M, Leslom S, Kahl BS, Ai WZ, Radford J, Solh M, Ardeshna KM, Hess BT, Lunning MA, Zinzani PL, Stathis A, Carlo-Stella C, Lossos IS, Caimi PF, Han S, Yang F, Kuker RA, Moskowitz CH. PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial. Clin Cancer Res. 2024 Jan 05;30(1):139-149. PMCID: PMC10872617

387. Mohan M, Kothari A, Verhagen N, Shreenivas A, Radhakrishnan SV, Dhakal B, Figueroa-Castro C, Chhabra S, Janz S, Pasquini M, Hamadani M, Szabo A, D'Souza A, N3C consortium. Blood and marrow transplant within 4 weeks of SARS-CoV-2 infection is associated with increased risk of mortality: a National COVID Cohort Collaborative (N3C) Study. Bone Marrow Transplant. 2024 Jan;59(1):121-124.

1. Hamadani M, Devine SM Patient evaluation before transplantation (adult). In: Wingard JR, Gastineau D, Leather H, Snyder EL, Szczepiorkowski ZM, eds. Hematopoietic Stem cell transplantation: a handbook for clinicians, 1st ed. Bethesda, MD AABB. 2009 Sept; 27-43

2. Hamadani M, Jaffe ES. Hodgkin lymphoma. In: Abraham J, Gulle JL, Allegra CJ, eds. The Bethesda Handbook of Clinical Oncology, 4th ed. Philadelphia, PA Lippincott Williams & Wilkins. 2014 March; 374-384

3. Lazarus HM, Hamadani M, Hari PN. Autologous hematopoietic cell transplantation. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 10th ed. Philadelphia, PA Lippincott Williams & Wilkins. 2014 Dec; 1907-1916

4. Hsu J, Hamadani M, Devine SM. Patient evaluation before transplantation (adult). In: Wingard JR, Gastineau D, Leather H, Snyder EL, Szczepiorkowski ZM, eds. Hematopoietic Stem Cell Transplantation: A Handbook for Clinicians, 2nd ed. Bethesda, MD AABB. 2015 Jan; 43-58

5. Saber W, Hamadani M, Hashmi S, Hari P. Lymphoma: working committee and data reporting after transplantation in lymphoma. In: Savani BN, Mohty M, eds. Clinical Guide to Transplantation in Lymphoma, 1st ed. Hoboken, NJ Wiley-Blackwell. 2015 Aug; 13-22

6. Kharfan-Dabaja MA, El-Jurdi N, Hamadani M, Ayala E. Preparative regimens for lymphoma: allogeneic hematopoietic stem cell transplantation. In: Savani BN, Mohty M, eds. Clinical Guide to Transplantation in Lymphoma, 1st ed. Hoboken, NJ Wiley-Blackwell; 2015 Aug; 57-68

7. Veltri L, Savani BN, Kharfan-Dabaja MA, Hamadani M, Kanate AS. Diffuse large B-cell lymphoma. In: Savani BN, Mohty M, eds. Clinical Guide to Transplantation in Lymphoma, 1st ed. Hoboken, NJ Wiley-Blackwell. 2015 Aug; 145-160

8. Epperla N, Hashami H, Hamadani M: “Hematopoietic cell transplantation in indolent non-Hodgkin lymphomas.” In: Abutalib SA., Hari P., eds. Clinical Manual of Blood and Bone Marrow Transplantation, 1st ed. Hoboken, NJ: Wiley-Blackwell; 2017: 140-150.

9. Hamadani M, Hari PN: “Indications and outcomes of allogeneic hematopoietic cell transplantation for hematologic malignancies in adults” In: Hoffman R.., Benz EJ Jr., Silberstein LE., Heslop H., Weitz J., Anastasi J., Abutalib SA., eds. Hematology: Basic Principles and Practice, 7th ed. Philadelphia, PA: Elsevier; 2017: 1596-1607.

10. Epperla N, Hamadani M, Horowitz MM: “Indications for allogeneic hematopoietic cell transplantation in adults.” In: Gluckman E., Niederwieser D., Aljurf M., eds. Establishing a Hematopoietic Stem Cell Transplantation Unit, 1st ed. Cham, Switzerland: Springer International Publishing AG. 2018: 83-110.

11. Lazarus HM, Hamadani M, Hari PN: “Autologous hematopoietic cell transplantation.” In: DeVita VT., Lawrence TS., Rosenberg SA., eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2019: 2008-2019.

12. Guru Murthy GS, Hamadani M, Hari PN. “Haploidentical hematopoietic cell transplantation in lymphomas.” In: Ciurea SO., Handgretinger R, eds. Haploidentical Transplantation: Concepts and Clinical Application, 1st ed. Cham, Switzerland: Springer International Publishing AG. 2018:245-260.

13. Kanate AS, Craig M, Hamadani M. “Hematopoietic cell transplantation.” In: Abraham J., Gulle JL., Allegra CJ., eds. The Bethesda Handbook of Clinical Oncology, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2019: 404-416.

1. Hamadani SM, Chaudhary L. Limitations of Sokal score in patients with chronic myeloid leukemia. J Coll Physicians Surg Pak. 2007 Mar;17(3):182; author reply 182.

2. Hamadani M, Kraut EH. Review: isolated skeletal involvement in hairy cell leukemia. Clin Adv Hematol Oncol. 2008 Apr;6(4):294-6.

3. Hamadani M, Blum W Role of hematopoietic stem cell transplantation in adults with acute myeloid leukemia. Clinical Leukemia. 2009 February; 3(1):47-57

4. Hamadani M, Mohty M, Kharfan-Dabaja MA. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. Cancer Control. 2011 Oct;18(4):237-45.

5. Chaudhary L, Hamadani M. Management strategies for follicular lymphoma patients in remission after modern frontline chemoimmunotherapies. J Blood Disorders Transf. 2013 January; 4(1):1000e105

6. Hamadani M. Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant? Bone Marrow Transplant. 2013 Aug;48(8):1013-21.

7. Hamadani M, Kanate AS Dawn of a new era: targeting the B-cell receptor signaling pathway to conquer B-cell lymphomas. Community Oncology. 2013 October;10(10):279-281

8. Hamadani M, Abu Kar SM, Usmani SZ, Savani BN, Ayala E, Kharfan-Dabaja MA. Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. Semin Hematol. 2014 Jan;51(1):73-86.

9. Hamadani M. Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simply in the eyes of the transplanter? Biol Blood Marrow Transplant. 2014 Mar;20(3):292-4.

10. Kanate AS, Pasquini MC, Hari PN, Hamadani M. Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. World J Stem Cells. 2014 Apr 26;6(2):69-81. PMCID: PMC3999783

11. Epperla N, Fenske TS, Hari PN, Hamadani M. Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. World J Transplant. 2015 Sep 24;5(3):81-8. PMCID: PMC4580930

12. Epperla N, Hamadani M. “Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances.” Hematol Oncol Stem Cell Ther. 2017 December;10(4):277-284.

13. Hamadani M, Horowitz MH. “Allogeneic transplantation for follicular lymphoma: Does one size fit all?” J Oncol Pract. 2017 Dec; 13(12):798-806.

14. Hamadani M. “Advances in transplantation for lymphomas resulting from CIBMTR Lymphoma Working Committee’s research portfolio: A five-year report (2013-2018).” Advances in Cell and Gene Therapy. 2018 Nov;1(3):e17-e21.

15. Hashmi H, Hamadani M, Awan FT. “Choosing the appropriate salvage therapy for B-cell non-Hodgkin lymphoma.” Expert Opin Pharmacother. 2018 Oct;19(15):1631-1634.

1. Mosallaei-Benjamin M, Hamadani M, Scofield H, Holla P, Selby G. The effects of hyperglycemia on hematopoietic stem cell transplantation. Poster Presentation: 39th Annual Meeting of the American Society of Hematology 1997, San Diego, CA.

2. Sethi S, Hamadani M, Kamble R, Kharfan-Dabaja M, Selby G, Ozer H. Pure red cell aplasia (PRCA) following ABO-incompatible allogeneic bone marrow transplantation. Poster Presentation: BMT Tandem Meetings 2005, Keystone, CO.

3. Hamadani M, Kamble R, Sethi S, Kharfan-Dabaja M, Kern W, Ozer H, Selby G. Elevated mean corpuscular volume (MCV) following autologous hematopoietic stem cell transplantation: incidence and significance. Poster Presentation: BMT Tandem Meetings 2005, Keystone, CO.

4. Hamadani M, Tfayli A, Kojouri K, Awab A. Comparison of ondansetron, granisetron, and dolasetron with dexamethasone in the prevention of acute nausea and vomiting associated with platinum-based therapy. Poster Presentation: ASCO 2005, Orlando, FL.

5. Hamadani M, Padmanabhan R, Chaudhary L, Tfayli A. Relative efficacy of various 5- hydroxytryptamine receptor antagonists in the prevention and control of acute nausea and vomiting associated with platinum-based chemotherapy. Poster Presentation: ASCO 2006, Atlanta, GA.

6. Hamadani M, Awan F, Elder P, Porcu P, Lin T, Blum K, Scholl D, Devine SM. Allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma: evidence of graft-versus-lymphoma effect. Poster Presentation: ASH 2007, Atlanta, GA.

7. Hamadani M, Hade EM, Elder P, Benson DM, Hofmeister CC. The effect of statin use at the time of autologous transplant on response and survival in patients with multiple myeloma. ASH 2007, Atlanta, GA.

8. Hamadani M, Elder P, Awan F, Krugh D, Blum W, Lin T, Andritsos L, Bechtel T, Blum K, Klisovic R, Devine SM. High rates of early donor chimerism and low risk of chronic GVHD can be achieved in poor risk patients undergoing unrelated donor stem cell transplantation using a reduced intensity conditioning regimen incorporating fludarabine, busulfan, and rabbit ATG. ASH 2007, Atlanta, GA.

9. Hamadani M, Phillips G, Elder P, Jansak B, Blum W, Penza S, Lin TS, Farag SS, Devine SM. Phase-II study of infliximab for the prophylaxis of acute graft-versus-host disease (GVHD) Following allogeneic hematopoietic stem cell transplantation (AHSCT). Poster Presentation: BMT Tandem Meetings 2008, San Diego, CA.

10. Hamadani M, Awan FT, Elder P, Lin TS, Andritsos L, Blum W, Blum KA, Devine SM. Rapid engraftment and low rates of graft-versus-host disease (GVHD) following reduced intensity conditioning (RIC) with fludarabine/busulfan/ATG (FBA) and Stem cell transplantation (SCT) using unrelated donors (URD). Poster Presentation: BMT Tandem Meetings 2008, San Diego, CA.

11. Hamadani M, Awan FT, Elder P, Devine SM. Statins reduce acute graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. Poster Presentation: ASCO 2008, Chicago, IL.

12. Awan FT, Hamadani M, Lin TS, Porcu P, Blum KA, Benson DM Jr, Devine SM. Comparison of allogeneic vs. autologous transplantation for follicular lymphoma after transformation into diffuse large B-cell lymphoma. Poster Presentation: ASCO 2008, Chicago, IL.

13. Hamadani M, Blum KA, Elder P, Lin TS, Porcu P, Hofmeister CC, Blum W, Marcucci G, Benson D, Devine S. Allogeneic stem cell transplantation for patients with chemo-refractory or progressive aggressive non-Hodgkin's lymphomas. Poster Presentation: ASH 2008, San Francisco, CA.

14. Hamadani M, Blum W, Benson D, Blum KA, Porcu P, Elder P, Krugh D, Bechtel T, Andritsos L, Garzon R, Penza S, Lin TS, Devine S. Assessment of rabbit antithymocyte globulin (rATG) dose-intensity in patients with hematological malignancies undergoing allogeneic stem cell transplantation (ASCT) following reduced intensity conditioning (RIC) with fludarabine, busulfan and rATG (FBA). ASH 2008, San Francisco, CA.

15. Benson D, Andritsos L, Hamadani M, Lin T, Flynn J, Jones J, Blum W, Elder P, Lozanski G, Byrd J, Devine S. Natural killer cell immune reconstitution predicts outcomes for patients with chronic lymphocytic leukemia undergoing allogeneic stem cell transplantation. Poster Presentation: ASH 2008, San Francisco, CA.

16. Ferreri AJM, Govi S, Dognini GP, Bouzani M, Bollinguer RC, D'Incan M, Delaporte E, Hamadani M, Jardin F, Martusewicz-Boros M, Montanari M, Szomor A, Crocchiolo R, Zucca E, Cavalli F, Ponzoni M. A cumulative series from 14 western countries suggests that rituximab significantly changed the dismal natural history of intravascular large B-cell lymphoma (IVL). Poster Presentation: ASH 2008, San Francisco, CA.

17. Andritsos L, Hamadani M, Heerema NA, Benson D, Hofmeister CC, Blum W, Flynn J, Jones JA, Elder P, Lin TS, Lozanski G, Byrd JC, Devine S. Attainment of minimal residual disease negative state is crucial for successful outcome of reduced intensity conditioning allogeneic stem cell transplantation in advanced chronic lymphocytic leukemia (CLL). Poster Presentation: ASH 2008, San Francisco, CA.

18. Pant S, Hamadani M, Crilley P, Szer J, Dodds AJ, Stevenson DE, Phillips G, Elder P, Nivison-Smith I, Avalos B, Penza P, Topolsky D, Sobecks R, Kalaycio M, Bolwell BJ, Copelan E. Incidence of late failure following myeloablative conditioning with BuCy2 and matched sibling allogeneic stem cell transplantation for acute myeloid leukemia. Poster Presentation: ASH 2008, San Francisco, CA.

19. Hamadani M, Benson DM, Porcu P, Elder P, Andritsos L, Hofmeister CC, Krugh D, Garzon R, Lin T, Marcucci G, Blum W, Devine SM. Evaluation of rabbit antithymocyte globulin (rATG) dose-intensity in patients undergoing allogeneic stem cell transplantation (ASCT) following reduced intensity conditioning (RIC) with fludarabine, busulfan and rATG (FBA). Oral Presentation: BMT Tandem Meetings 2009, Tampa, FL.

20. Hamadani M, Baiocchi R, Lin T, Blum KA, Ezzone S, Benson DM, Devine SM. Feasibility of allogeneic peripheral blood stem cell transplantation (Allo-SCT) following reduced intensity conditioning (RIC) in HIV+ patients with hematological malignancies. Poster Presentation: BMT Tandem Meetings 2009, Tampa, FL.

21. Benson DM, Hofmeister CC, Hamadani M, Panzner K, Smith MK, Penza SL, Elder P, Krugh D, O'Donnell L, Devine SM. Pre-mobilization bone marrow plasmacytosis predicts successful stem cell mobilization in patients with multiple myeloma receiving lenalidomide based induction regimens. Poster Presentation: BMT Tandem Meetings 2009, Tampa, FL.

22. Grauer A, Hamadani M, Blum KA, Porcu P, Benson DM, Devine SM. Allogeneic versus autologous stem cell transplantation (SCT) for follicular lymphoma (FL). The James comprehensive cancer center experience. Poster Presentation: BMT Tandem Meetings 2009, Tampa, FL.

23. Hamadani M, Liu K, Anthony BA, Gaughan A, Wang JJ, Shana'ah A, Byrd JC, Devine SM, Johnson AJ, Hadley GA. CD103 deficiency separates graft-versus-host disease and graft-versus-leukemia effects mediated by donor CD8T Cells. Poster Presentation: BMT Tandem Meetings 2010, Orlando, FL.

24. Hamadani M, Craig M, Abraham J, Tse W, Cumpston A, Stotler CJ, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Andritsos L, Blum W, Benson DM, Devine SM. Evaluation Of busulfan's dose-intensity in patients undergoing allogeneic stem cell transplantation (ASCT) with two different fludarabine/busulfan/ATG (FBA)-based reduced intensity conditioning (RIC) regimens. Poster Presentation: BMT Tandem Meetings 2010, Orlando, FL.

25. Jaglowski SM, Heerema N, Elder P, Scholl D, Hamadani M, Byrd JC, Devine S, Andritsos LA. Complex karyotype predicts poor response to salvage therapy and ineligibility for reduced intensity conditioning transplantation in CLL . Poster Presentation: BMT Tandem Meetings 2010, Orlando, FL.

26. Osman S, Kanate AS, Bunner P, Leadmon S, Tse W, Cumpston A, Gibson L, Remick S, Abraham J, Craig M, Hamadani M. Response to induction chemotherapy with novel agents does not predict outcomes of multiple myeloma patients undergoing autologous hematopoietic cell transplantation. Poster Presentation: ASH 2010, Orlando, FL.

27. Kanate AS, Osman S, Cumpston A, Hobbs G, Leadmon L, Bunner P, Watkins W, Gibson L, Tse W, Abraham J, Remick S, Craig M, Hamadani M. Higher infused CD34+ cell dose improves survival in patients undergoing in-vivo T-cell depleted, but not T-cell replete peripheral blood hematopoietic cell transplant. Poster Presentation: ASH 2010, Orlando, FL.

28. Awan F, Osman S, Kochuparambil ST, Remick S, Abraham J, Craig M, Jillella AP, Hamadani M. Impact of response to thalidomide, lenalidomide or bortezomib containing induction chemotherapy on outcomes of multiple myeloma patients undergoing autologous transplantation - A multicenter analysis. Poster Presentation: ASH 2010, Orlando, FL.

29. Kanate AS, Osman S, Cumpston A, Hobbs G, Leadmon L, Bunner P, Watkins W, Gibson L, Tse W, Abraham J, Remick S, Craig M, Hamadani M. In-vivo T-cell depletion does not improve rates of graft-versus-host disease and transplantation outcomes in patients undergoing peripheral blood hematopoietic cell transplant. ASH 2010, Orlando, FL.

30. Stauffer N, Hamadani M, Heaphy C, Santhanam R, Sandhu S, Costinean S, Nuovo J, Perrotti D, Croce CM, Hadley G, Marcucci G, Devine SM, Garzon R. Regulation of acute graft-versus-host disease by microRNA-155. Oral Presentation: ASH 2010, Orlando, FL.

31. Hamadani M, Craig M, Abraham J, Tse W, Cumpston A, Gibson LF, Remick SC, Leadmon S, Elder P, Hofmeister C, Penza S, Andritsos L, Blum W, Benson DM, Devine SM. Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic hematopoietic cell transplantation following fludarabine/busulfan/ATG-based reduced toxicity conditioning. Poster Presentation: BMT Tandem Meetings 2011, Honolulu, HI.

32. Kanate AS, Osman S, Cumpston A, Hobbs G, Leadmon S, Bunner P, Gibson L, Tse W, Abraham J, Remick S, Craig M, Hamadani M. In vivo T-cell depletion does not improve rates of graft-versus-host disease and transplantation outcomes in patients undergoing peripheral blood allogeneic hematopoietic cell transplant. Poster Presentation: BMT Tandem Meetings 2011, Honolulu, HI.

33. Osman S, Kanate A, Bunner P, Leadmon S. Hart K, Goff L, Tse W, Cumpston A, Remick S, Abraham M, Craig M, Hamadani M. Cyclophosphamide/G-CSF cannot completely overcome Imid-induced impairment of peripheral blood stem cell mobilization in patients with multiple myeloma. Poster Presentation: BMT Tandem Meetings 2011, Honolulu, HI.

34. Kanate AS, Chaudhary L, Cumpston A, Leadmon S, Bunner P, Bulian D, Gibson L, Tse W, Abraham J, Remick S, Craig M, Hamadani M. High rates of non-relapse mortality and graft-versus-host disease in patient undergoing allogeneic stem cell transplantation following non-myeloablative conditioning with TLI/ATG. Poster Presentation: BMT Tandem Meetings 2011, Honolulu, HI.

35. Anthony B, Hamadani M, Wang JJ, Gaughan A, Hadley GA. CD103 blockade reduces CD8 T cell accumulation during GVHD, but does not attenuate GVL effects. Poster Presentation: AAI 2011, San Francisco, CA.

36. Covey T, Gulrajani M, Hawtin R, Gayko U, Cumpston A, Craig M, Hamadani M, Rishel A, Park J, Abraham J, Remick S, Tse W. Integrating in vitro signaling and drug response data from single cell network profiling (SCNP) to inform on individual's AML biology. Poster Presentation: AACR-NCI-EORTC International Conference 2011, San Francisco, CA.

37. Hamadani M, Kochuparambil TS, Osman S, Speir E, Craig M, Deremer D, Cumpston A, Morrison DD, Leadmon S, Sterling K, Bunner P, Sterrett M, Kota V, Jillella AP, Awan FT. Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies - A Multicenter Analysis. Oral Presentation: ASH 2011, San Diego, CA.

38. Kharfan-Dabaja M, Hamadani M, Reljic T, Bensinger W, Djulbegovic B, Kumar A. Comparative efficacy of tandem autologous-autologous versus tandem autologous-reduced intensity allogeneic haematopoietic cell transplantation in multiple myeloma: results of a systematic review and meta-analysis. Oral Presentation: BMT Tandem Meetings 2012, San Diego, CA.

39. Forero A, Hamadani M, Goswami T, Sonet A, Verhoef G, Fanale MA, Bello CM, Huang W, Cheson BD. Phase I/II study of MEDI-551, a humanized monoclonal antibody targeting CD19, in subjects with relapsed or refractory advanced B-cell malignancies. Poster Presentation: ASCO 2012, Chicago, IL.

40. Richardson P, Berdeja J, Niesvizky R, Lonial S, Vesole D, Hamadani M, Chari A, Hari P, Htut M, Roy V, Stewart K, Berg D, Lin L, Gupta N, Di Bacco A, Hui A-M, Kumar S. MLN9708, an investigational proteasome inhibitor, combine with lenalidomide and dexamethasone in previously untreated multiple myeloma patients: Evaluation of weekly and twice-weekly dosing regimens. Oral Presentation: 17th Congress of the EHA 2012, Amsterdam, NL.

41. Kumar S, Berdeja J, Niesvizky R, Lonial S, Hamadani M, Stewart A, Roy V, Hari P, Vescio R, Berg D, Lin J, Bacco A, Gupta N, Hui Ai, Richardson P. A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma. Oral Presentation: ASH 2012, Atlanta, GA.

42. Lust J, Usmani S, Hamadani M, Barranco C, Lacy M, Dispenzieri A, Gertz M, Dingli D, Russell S, Buadi F, Zeldenrust S, Hayman S, Rajkumar S, Kumar S, Thompson J, Taylor C, Dondero R. Phase 1b/2a dose-escalation study to evaluate the safety and tolerability of SNS01-T administered by intravenous infusion in patients with relapsed or refractory multiple myeloma. Poster Presentation: ASH 2012, Atlanta, GA.

43. Forero A, Hamadani M, Fanale M, Bello C, Kipps T, Offner F, Verhoef G, Federico M, Gregory S, Sonet A, Assouline S, Oteyza J, Tomas J, Cuneo A, Zhang W, Goswami T, Ibrahim R, Yao Z, Herbst R, Cheson B. MEDI-551, a humanized monoclonal anti-CD19, in adults with relapsed or refractory advanced B-cell malignancies: results from a phase 1/2 study. Poster Presentation: ASH 2012, Atlanta, GA.

44. Hamadani M, Craig M, Remick S, Gibson L, Petros W, Abraham J, Cumpston C, Bunner P, Basu B, Tse W, Hennelly C, Vasu S, Klisovic R, Blum W, Jaglowski S, Benson, D, Andritsos L, Penza S, Hofmeister C, Geyer S, Devine S, Efebera Y. Immunomodulation of both donors and recipients with atorvastatin as a strategy for the prevention of acute graft-versus-host disease: results of two parallel prospective trials in recipients of matched sibling allogeneic hematopoietic cell Transplantation. Poster Presentation: ASH 2012, Atlanta, GA.

45. Hamadani M, Saber W, Carreras J, Ahn K, Laport G, Montoto S, Maloney D, Lazarus M. Impact of conditioning regimen intensity on the outcomes of allogeneic hematopoietic cell transplantation for refractory grade-III follicular and diffuse large B-cell lymphomas: A CIBMTR Analysis. Oral Presentation: ASH 2012, Atlanta, GA.

46. Hamadani M, Saber W, Carreras J, Ahn K, Laport G, Montoto S, Maloney D, Lazarus M. Effect of graft source and transplant conditioning regimen intensity on the outcomes of allogeneic hematopoietic cell transplantation for refractory mantle cell lymphoma: A CIBMTR Analysis. Oral Presentation: ASH 2012, Atlanta, GA.

47. Awan F, Kochuparambil S, Craig M, Cumpston A, Leadmon S, DeRemer D, Watkins K, Pantin J, Kota V, Jillella A, Hamadani M. A multicenter analysis of intermediate-dose cyclophosphamide versus plerixafor and granulocyte-colony stimulating factor for PB progenitor cell mobilization in patients with multiple myeloma treated with novel induction chemotherapies. Poster Presentation: BMT Tandem Meetings 2013, Salt Lake City, UT.

48. Veltri L, Regier M, Kanate A, Cumpston A, Leadmon S, Abraham J, Craig M, Hamadani M. Incidence and pattern of graft-versus-host disease in patients undergoing allogeneic hematopoietic cell transplantation after non-myeloablative conditioning with total lymphoid irradiation and antithymocyte globulin. Poster Presentation: BMT Tandem Meetings 2013, Salt Lake City, UT.

49. Hamadani M, Gibson L, Remick S, Petros W, Abraham J, Basu S, Tse W, Cumpston A, Bunner P, Craig M. Prospective evaluation of a 'two-pronged' strategy of atorvastatin administration as acute graft-versus-host disease prophylaxis, to both donors and recipients of matched related donor allogeneic hematopoietic cell transplantation. Oral Presentation: BMT Tandem Meetings 2013, Salt Lake City, UT.

50. Kharfan-Dabaja M, Nishihori T, Reljic T, Vazquez-Otero C, Baz R, Hamadani M, Ochoa-Bayona J, Alsina M, Djulbegovic B, Kumar A. Comparing efficacy of double- versus triple-combination therapy in newly diagnosed, transplant-eligible, patients with multiple myeloma: results of a metaanalysis. Poster Presentation: EBMT 2013, London, UK.

51. Chaudhary L, Awan F, Cumpston A, Tse W, Craig M, Hamadani M. Efficacy and cost of peripheral blood stem cell mobilization with low-dose cyclophosphamide compared with plerixafor in multiple myeloma patients treated with novel induction therapies. Poster Presentation: ASCO 2013, Chicago, IL.

52. Cooper BW, Kindwall-Keller T, Lazarus H, Hamadani M, Tse W, Basu S, Craig M. Phase I study of midostaurin and azacitidine in relapsed and elderly AML. Poster Presentation: ASCO 2013, Chicago, IL.

53. Truong QV, Shah N, Knestrick M, Curley B, Craig M, Hamadani M. Limited utility of surveillance imaging for detection of relapse in non-Hodgkin lymphoma. Poster Presentation: ASCO 2013, Chicago, IL.

54. Hamadani M, Forero A, Kipps T, Fanale M, Cuneo A, Perez de Oteyza J, Gladstone D, Goswami T, Ibrahim R, Liang M, Eck S, Elgeioushi N, Herbst R, Cheson BD. MEDI-551, an anti-CD19 antibody active in chronic lymphocytic leukemia (CLL) patients previously treated with rituximab. Poster Presentation: ASCO 2013, Chicago, IL.

55. Younes A, Radford J, Ansell S, Gallamini A, Kim W, Feldman T, Hamadani M, Chung J, Wang J, Huebner D, Connors JM. Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine versus doxorubicin, bleomycin, vinblastine, and dacarbazine as front-line treatment for advanced classical Hodgkin lymphoma. Poster Presentation: ASCO 2013, Chicago, IL.

56. Richardson P, Berdeja J, Niesvizky R, Lonial S, Hamadani M, Stewart A, Hari P, Vesole D, Roy V, Berg D, Lin J, Hui A, Kumar S. Weekly oral investigational proteasome inhibitor MLN9708 plus lenalidomide-dexamethasone in elderly patients with previously untreated multiple myeloma: Subset analysis of a phase I/II study. Poster Presentation: 18th Congress of the EHA 2013, Stockholm, SE.

57. Efebera Y, Ranganathan P, Yu X, Hofstetter J, Garman S, Gibson F, Petros W, Craig M, Fernandez-Cymering C, Volinia S, Hamadani M, Marcucci G, Devine S, Garzon R. Serum microRNA signature in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Poster Presentation: 18th Congress of the EHA 2013, Stockholm, SE.

58. Brown J, Hamadani M, Arnason J, Karlin L, Hayslip J, Wagner-Johnston N, Cartron G, Ribrag V, Guibert S, Ganguly S, Ailawadhi S, Ruiz-Soto R, Kersten M. SAR245409 monotherapy in relapsed, refractory follicular lymphoma: preliminary results from the phase II ARD12130 study. Oral Presentation: ASH 2013, New Orleans, LA.

59. Forero-Torres A, Hamadani M, Fanale M, Bello C, Kipps T, Offner F, Verhoef G, Sonet A, Cuneo A, Goswami T, Ibrahim R, Cheson B. Safety profile and clinical response to MEDI-551, a humanized monoclonal anti-CD19, in a phase 1/2 study in adults with relapsed or refractory advanced B-cell malignancies. Poster Presentation: ASH 2013, New Orleans, LA.

60. Lust J, Barranco C, Usmani S, Rhee R, Hamadani M, Dondero R, Browne L, Siegel D, Bensinger W. Phase 1b/2a open-label, dose-escalation study to evaluate the safety and tolerability of of SNS01-T in patients with relapsed/refractory multiple myeloma, mantle cell lymphoma, or diffuse large B cell lymphoma. Poster Presentation: ASH 2013, New Orleans, LA.

61. Efebera Y, Ranganathan P, Gibson L, Craig M, Fernandez-Cymering C, Hamadani M, Marcucci G, Devine SM, Fabbri M, Garzon R. Serum Mir-29a is up-regulated in acute graft versus host disease after allogeneic hematopoietic stem cell transplantation and activates dendritic cells. Poster Presentation: ASH 2013, New Orleans, LA.

62. Kanate A, Rauenzahn S, Leadmon S, Truong Q, Cumpston A, Londia L, Evans K, Zhang J, Wen S, Craig M, Hamadani M. Predictors and impact of 30-day readmissions on patient outcomes and healthcare costs after allogeneic transplantation. Poster Presentation: ASH 2013, New Orleans, LA.

63. Forero A, Hamadani M, Kipps T, Fanale M, Cuneo A, Gladstone D, Andre M, Bellam N, Goswami T, Ibrahim R, Eck S, Elgeioushi N, Herbst R, Cheson B. Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab. Poster Presentation: SITC 2013, National Harbor, MD.

64. Shah N, Rauenzahn S, Wen S, Craig M, Kanate A, Hamadani M, Cumpston A. Long term outcomes of autologous hematopoietic cell transplant following thiotepa-based high-dose therapy in patients with non-Hodgkin lymphoma. Poster Presentation: BMT Tandem Meetings 2014, Grapevine, TX.

65. Kumar A, Reljic T, Hamadani M, Castrovinci P, Nishihori T, Ayala E, Savani B, Djulbegovic B, Kharfan-Dabaja M. Efficacy of high-dose therapy and autologous hematopoietic cell transplantation intensification after rituximab-based front-line treatment of aggressive lymphomas: results of a systematic review and meta-analysis. Poster Presentation: EBMT 2014, Milan, IT.

66. Dhakal B, Strouse C, Arce-Lara C, D'Souza A, Esselman J, Eastwood D, Pasquini C, Saber W, Drobyski W, Hari P, Hamadani M. Plerixafor plus G-CSF (P+G) compared with G-CSF alone (G) for hematopoietic progenitor cell (HPC) mobilization in AL amyloidosis (AL). Poster Presentation: ASCO 2014, Chicago, IL.

67. Hamadani M, Hari P, Zhang Y, Carreras J, Maloney D, Smith S, Montoto S, Saber W. Early rituximab failure (ERF) in relapsed diffuse large b-cell lymphoma (DLBCL) and prediction of futility of autologous hematopoietic cell transplantation (AHCT). Poster Presentation: ASCO 2014, Chicago, IL.

68. Gonzalez R, Shillingburg A, Newton M, Wen S, Leadmon S, Kanate A, Craig M, Hamadani M, Cumpston C. Impact of body mass index (BMI) on plerixafor efficacy during hematopoietic progenitor cell (HPC) mobilization. Poster Presentation: ASCO 2014, Chicago, IL.

69. Kumar S, Berdeja J, Niesvizky R, Lonial S, Laubach J, Hamadani M, Stewart K, Hari P, Roy V, Vescio R, Kaufman J, Berg D, Liao E, Hui A, Rajkumar S, Richardson P. Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomib-lenalidomide-dexamethasone induction in patients with previously untreated multiple myeloma: phase 2 study results. Oral Presentation: ASH 2014, San Francisco, CA.

70. Veltri L, Cumpston A, Shillingburg A, Lipinski C, Wen S, Leadmon S, Watkins K, Craig M, Hamadani M, Kanate A. Cost and efficacy of upfront plerixafor versus a “just-in-time” (JIT) approach in hematopoietic progenitor cell (HPC) mobilization. Poster Presentation: ASH 2014, San Francisco, CA.

71. Satwani P, Ahn K, Carreras J, Maloney D, Sureda A, Smith S, Hamadani M. Risk factors predicting outcomes of autologous hematopoietic cell transplantation (autoHCT) in children, Adolescents and young adults (CAYA) with relapsed/refractory (Rel/Ref) classical Hodgkin lymphoma (HL): A CIBMTR analysis. Oral Presentation: BMT Tandem Meetings 2015, San Diego, CA.

72. Bachanova V, Burns L, Ahn K, Carreras J, Maloney D, Sureda A, Smith S, Hamadani M. Positive pre-allogeneic hematopoietic cell transplantation (alloHCT) PET scan in patients with non-Hodgkin lymphoma (NHL) predicts higher risk of relapse but has no impact on survival. Oral Presentation: BMT Tandem Meetings 2015, San Diego, CA.

73. Klyuchnikov E, Bacher U, Kröger N, Hari P, Ahn K, Maloney D, Smith S, Sureda A, Carreras J, Hamadani M. Association of reduced intensity conditioning (RIC) allograft (alloHCT) as first transplant approach in relapsed/refractory grade 3(G-3) follicular lymphoma (FL) with improved outcomes in long-term survivors. Oral Presentation: ASCO 2015, Chicago, IL.

74. Veltri L, Dhakal B, Singavi A, Wen S, Luo J, Craig M, Cumpston A, Shillingburg A, Watkins K, Esselman J, Pasquini M, Fenske T, Hari P, Hamadani M, Kanate A. Chemomobilization with (R)-ICE (rituximab, ifosfamide, carboplatin, etoposide) compared to G-CSF and plerixafor (G+P) mobilization in lymphoid malignancies. Poster Presentation: ASCO 2015, Chicago, IL.

75. Klyuchnikov E, Bacher U, Kröger N, Hari P, Ahn K, Maloney D, Smith S, Sureda A, Carreras J, Hamadani M. Reduced intensity conditioning (RIC) allo transplantation is associated with superior long-term disease control in relapsed/refractory grade I/II (G-I/II) follicular lymphoma. Oral Presentation: 19th Congress of the EHA 2015, Milan, IT.

76. Sureda A, Zhang M, Dreger P, Carreras J, Fenske T, Finel H, Schouten H, Montoto S, Robinson S, Smith S, Boumendil A, Hamadani M, Pasquini M. Allogeneic stem cell transplantation for relapsed/refractory (R/R) follicular lymphoma (FL). a joint study between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). Oral Presentation: ASH 2015, Orlando, FL.

77. Kharfan-Dabaja M, Reljic T, El-Asmar J, Nishihori T, Ayala A, Hamadani M, Ambuj K. Myeloablative or reduced intensity conditioning allogeneic hematopoietic cell transplantation for mantle cell lymphoma? a systematic review and meta-analysis. Poster Presentation: ASH 2015, Orlando, FL.

78. Dhakal B, Ramalingam S, Shuff J, Epperla N, Rein L, Banerjee A, Siker M, Hosking P, Hari P, D'Souza A, Atallah E, Erisckson B, Fenske T, Hamadani M. Local control of ocular adnexal lympho-proliferative disorders (OALD): Similar Outcomes in MALT and non-MALT histologies. Poster Presentation: ASH 2015, Orlando, FL.

79. El-Asmar J, Reljic T, Ayala A, Nishihori T, Hamadani M, Ambuj K, Kharfan-Dabaja M. Efficacy of high-dose therapy and autologous hematopoietic cell transplantation in peripheral T-cell lymphomas as front-line consolidation or in the relapsed/refractory setting: a meta-analysis. Poster Presentation: ASH 2015, Orlando, FL.

80. Scott B, Pasquini M, Logan B, Wu J, Devine S, Porter D, Maziarz R, Warlick E, Fernandez H, Alyea E, Hamadani M, Bashey A, Giralt S, Leifer E, Geller N, Le-Rademacher J, Mendizabal M, Horowitz M, Deeg J, Horwitz M. Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. Oral Presentation: ASH, 2015, Orlando, FL.

81. Mussetti A, Kanate A, Kharfan-Dabaja M, Ahn K, DiGilio A, Ciurea S, Armand P, Salit R, Fenske T, Smith S, Sureda A, Bolanos-Meade J, Hamadani M. Survival after T-cell replete haploidentical related donor transplant using post-transplant cyclophosphamide compared with matched unrelated donor (MUD) transplant for lymphoid malignancies. Oral Presentation: ASH 2015, Orlando, FL.

82. Chen Y, Le-Rademacher J, Kiefer D, Hamadani M, DiPersio J, Litzow M, Craig M, Horwitz M, Artz A, McClune B, Waller E, Fernandez H, Duong H, Kobusingye H, Proue M, Drexler R, Horowitz M, Miller J, Devine S. A Phase II study evaluating the safety and efficacy of subcutaneous plerixafor for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells in recipients with hematological malignancies. Oral Presentation: ASH 2015, Orlando, FL.

83. Fenske T, Graff T, Ahn K, Digilio A, Smith S, Sureda A, Hamadani M. Reduced-intensity allogeneic hematopoietic cell transplantation (allo-HCT) provides durable progression-free survival (PFS) in a subset of diffuse large B-cell lymphoma (DLBCL) patients relapsing after autologous (auto-) HCT. Oral Poster Presentation: ASH 2015, Orlando, FL.

84. Hamadani M, Pasquini MC, Visotcky A, Ahn KW, Horowitz M, Boyd J, Rizzo J, Saber W, Drobyski W, Arce-Lara C, D'Souza A, Fenske T, Cumpston A, Bunner P, Craig M, Hari P, Kanate A. Prospective, multicenter clinical trial of atorvastatin-based acute graft-versus-host-disease (aGVHD) prophylaxis in recipients of HLA-matched related donor (MRD) and matched unrelated donor (MUD) allogeneic hematopoietic cell transplantation (alloHCT). Oral Presentation: BMT Tandem Meetings 2016, Honolulu, HI.

85. Karmali R, Ghosh N, Rocha V, Ahn K, DiGilio A, Armand P, Salit R, Fenske T, Smith S, Sureda A, Johnston N, Bolanos-Meade J, Hamadani M Survival after T-cell replete haploidentical related donor hematopoietic cell transplantation (Haplo-HCT) using post-transplant cyclophosphamide (PT-CY) compared with HLA-matched related donor (MRD) transplant for lymphomas. Oral Presentation: BMT Tandem Meetings 2016, Honolulu, HI.

86. Shillingburg A, Craig M, Kanate A, Hamadani M, Cumpston A Treatment of severe mucositis pain with oral ketamine mouthwash. Biology of Blood and Marrow Transplantation. Poster Presentation: BMT Tandem Meetings 2016, Honolulu, HI.

87. Hari P, Kanate A, Pasquini M, Saber W, Drobyski W, Horowitz M, Rizzo J, Craig M, Hamadani M. Atorvastatin is effective for graft versus host diseas prophylaxis – Results of a phase II prospective trial. Oral Presentation: EBMT 2016, Valencia, Spain.

88. Sureda A, Zhang M, Dreger P, Carreras J, Fenske T, Finel H, Schouten H, Montoto S, Robinson S, Smith S, Boumendil A, Hamadani M, Pasquini M. Allogeneic stem cell transplantation for relapsed/refractory (R/R) follicular lymphoma (FL). A joint study between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). Oral Presentation: EBMT 2016, Valencia, Spain.

89. Mateos M, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson S, Stoppa A, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Velde H, Richardson P, Moreau P. “Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1. Poster Presentation: ASCO 2016, Chicago, IL.

90. Chung Ki, Hamadani M, Kahl B, Heffner L, Caimi P, Feingold J, O'Connor O. A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (B-NHL). Poster Presentation: ASCO 2016, Chicago, IL.

91. Guru Murthy G, Mehta P, Hari P, Hamadani M. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL). Poster Presentation: ASCO 2016, Chicago, IL.

92. Epperla N, Hamadani M, Ahn K, Oak E, Cashen A, Kanate A, Calzada O, Farmer Z, Tallarico M, Nabhan C, Costa L, Kenkre V, Ghosh N, Cohen J, Hari P, Fenske T. Allogeneic hematopoietic cell transplantation (AHCT) for hematological malignancies (HM) in United States: A comparison of hospitalization outcomes between young and elderly patients.Poster Presentation: ASCO 2016, Chicago, IL.

93. Kline J, Armand P, Kuruvilla J, Moskowitz C, Hamadani M, Ribrag V, Zinzani P, Chlosta S, Thompson S, Balakumaran A, Bartlett N: “KEYNOTE-013: An open-label, multicohort phase 1b trial of pembrolizumab for advanced hematologic malignancies.” Journal for ImmunoTherapy of Cancer. 2016;4:Suppl 1. [Poster Presentation]

94. Khalil M, Reljic T, El-Asmar, Hamadani M, Nishihori T, Ayala E, Kumar A, Kharfan-Dabaja M: “Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for myelofibrosis: A side-by-side systematic review/meta-analysis”Blood (ASH Annual Meeting Abstracts), 2016;128:3551. [Poster Presentation]

95. Costa L, Landau H, Chhabra S, Hari P, Salzman D, Saad A, Innis-Shelton R, Hamadani M, Tamari R, Godby K, Petrovic V, Orlando E, Williams L, Dixon P, Giralt S: “Carfilzomib plus high dose melphalan conditioning prior to autologous hematopoietic cell transplantation followed by carfilzomib maintenance in patients with relapsed multiple myeloma.” Blood (ASH Annual Meeting Abstracts), 2016;128:4630. [Poster Presentation]

96. Wang M, Martin P, Phillips T, Goy A, Lossos I, Rule S, Hamadani M, Ghosh N, Reeder C, Barnett E, Bravo M, Schuster S: “Effectiveness of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib: The MCL-004 study.” Blood (ASH Annual Meeting Abstracts), 2016;128:1786. [Poster Presentation]

97. Bashey A, Zhang M, McCurdy S, Ciurea S, Martin A, Anasetti C, Argall T, Fasan O, Gaballa S, Hamadani M, Al-Malki M, Munshi P, Nakamura R, O’Donnell P, Perales M, Raj K, Rocha V, Romee R, Rowley S, Salit R, Solh M, Soiffer R, Wingard J, Weisdorf D, Horowitz M, Fuchs E, Eapen M: “Comparison of peripheral bood stem cells (PBSC) to bone marrow (BM) for T-replete HLA-haploidentical donor transplantation using post-transplant cyclophosphamide.” Blood (ASH Annual Meeting Abstracts), 2016;128:683. [Oral Presentation]

98. Maddocks K, Epperla E, Chavez J, Reddy N, Karmali R, Umyarova E, Costa C, Bachanova V, Glenn M, Calzada O, Xavier A, Zhou Z, Hossain N, Hernandez-Ilizaliturri F, Al-Mansour Z, Barta S, Chhabra S, Lansigan F, Mehta A, Jaglal M, Evans E, Peker D, Forero-Torres A, Flowers C, Fenske T, Cohen J, Hamadani M, Costa L: “Diffuse large B-cell Lymphoma with primary treatment failure: identification of ultra-high risk patients and benchmarking for experimental therapies.” Blood (ASH Annual Meeting Abstracts), 2016;128:103. [Oral Presentation]

99. Costa L, Reddy N, Maddocks K, Epperla E, Chavez J, Karmali R, Umyarova E, Costa C, Bachanova V, Glenn M, Calzada O, Xavier A, Zhou Z, Hossain N, Hernandez-Ilizaliturri F, Al-Mansour Z, Barta S, Chhabra S, Lansigan F, Mehta A, Jaglal M, Evans E, Peker D, Forero-Torres A, Flowers C, Fenske T, Cohen J, Hamadani M: “Primary failure diffuse large B-cell lymphoma: early autologous or donor hematopoietic cell transplantation not effective in patients with ultra-high risk features.” Blood (ASH Annual Meeting Abstracts), 2016;128:103. [Oral Presentation]

100. Casulo C, Friedberg JW, Ahn K, DiGilio A, Sureda A, Fenske T, Smith S, Hamadani M: “Autologous transplantation (autoHCT) is associated with improved overall survival (OS) in follicular lymphoma (FL) patients (Pts) experiencing early therapy failure after frontline chemo-immunotherapy: A National Lymphocare Study (NLCS) & CIBMTR Analysis.” Biology of Blood and Marrow Transplantation. March 2017;23(3):S46-47. [Oral Presentation]

101. Epperla N, Kodali D, Kleman A, Hari P, Pasquini M, D'Souza A, Saber W, Shah N, Fenske T, Craig M, Kanate A, Hamadani M: “Post-relapse survival in lymphoma patients (Pts) after experiencing therapy failure following an allogeneic hematopoietic cell transplantation (alloHCT).” Biology of Blood and Marrow Transplantation. March 2017;23(3):S48. [Oral Presentation]

102. Epperla N, Ahn K, DiGilio A, Jagasia M, Armand P, Ahmed S, Devine S, Jaglowski S, Kharfan-Dabaja M, Kennedy V, Rezvani A, Smith S, Sureda A, Fenske T, Hamadani M: “Rituximab (R) versus non-rituximab (NR) containing reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in B-cell non-Hodgkin lymphomas (B-NHL): A CIBMTR Analysis.” Biology of Blood and Marrow Transplantation. March 2017;23(3):S47-S48. [Oral Presentation]

103. Kanate A, Olteanu H, Ahn K, DiGilio A, Sureda A, Fenske T, Smith S, Hamadani M: “Allogeneic hematopoietic cell transplantation (alloHCT) for extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL): A CIBMTR analysis.” Biology of Blood and Marrow Transplantation. March 2017;23(3):S49-S50. [Oral Presentation]

104. Godfrey J, Smith S, Ahn K, Digilio A, Fenske T, Sureda A, Hamadani M: “Autologous (auto) versus matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic (allo) hematopoietic cell transplantation (HCT) in follicular lymphoma (FL) patients (pts) with early chemoimmunotherapy failure (ECF): A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.” J Clin Oncol. 2017;35:(suppl; abstr 7508). [Oral Presentation]

105. Horwitz SM, Fanale M, Spira A, Havenith K, He S, Feingold J, Hamadani M: “Interim data from the first clinical study of ADCT-301, a novel pyrrolobenzodiazapine-based antibody drug conjugate, in relapsed/refractory Hodgkin/non-Hodgkin lymphoma.” Hematol Oncol. 2017 35: Supplement S2. 14-ICML, 14th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano (Switzerland). [Poster Presentation]

106. Kahl B, Hamadani M, Caimi P, Reid E, Havenith K, He S, Feingold J, O’Connor O: “First clinical results of ADCT-402, a novel pyrrolobenzodiazapine-based antibody drug conjugate, in relapsed/refractory B-cell non-Hodgkin lymphoma.” 2017 35: Supplement S2. 14-ICML, 14th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano (Switzerland). [Oral Presentation]

107. Horwitz S, Hamadani M, Fanale M, Feingold J, Spira A, Fields P, Menne T, Karnad A, Moskowitz A, Hildyard C, He S, Boni J. Collins G: “Interim results from a phase 1 study of ADCT-301 (camidanlumab tesirine) show promising activity of a novel pyrrolobenzodiazepine-based antibody drug conjugate in relapsed/refractory Hodgkin/non-Hodgkin lymphoma.” Blood (ASH Annual Meeting Abstracts), 2017;130:1510. [Poster Presentation]

108. Pawarode A, D'Souza A, Pasquini M, Johnson B, Braun T, Dhakal B, Hamadani M, Magenau J, Shah N, Riwes M, Parkin B, Reddy P, Hari P: “Phase 2 study of pembrolizumab during lymphodepleted state after autologous hematopoietic cell transplantation in multiple myeloma patients.” Blood (ASH Annual Meeting Abstracts), 2017;130:339. [Oral Presentation]

109. Kahl B, Hamadani M, Caimi P, Carlo-Stella C, Reid E, Feingold J, Ardeshna K, Radford J, Solh M, Chung K, Heffner L, He S, Boni J, O'Connor O: “Encouraging early results from the first in-human clinical trial of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory B-cell lineage non-Hodgkin lymphoma.” Blood (ASH Annual Meeting Abstracts), 2017;130:187. [Oral Presentation]

110. Chhabra S, Hari P, Visotcky A, Shah N, Rizzo J, Saber W, D'Souza A, Dhakal B, Anshu A, Thompson R, Fenske T, Shaw B, Drobyski W, Pasquini M Hamadani M: “Ixazomib for chronic graft-versus-host-disease (cGVHD) prophylaxis in patients undergoing allogeneic transplantation (alloHCT): Preliminary results of a phase I/II study.” Blood (ASH Annual Meeting Abstracts), 2017;130:1974. [Poster Presentation]

111. Badar T, Hamadani M, Bachanova V, Maddocks K, Umyarova E, Chavez J, Epperla N, Chhabra S, Xavier A, Karmali R, Salhab M, Reddy N, Hernandez-Ilizaliturri F, Flowers C, Evens A, Zhou Z, Lansigan F, Barta S, Cohen J, Fenske T, Costa L: “Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin.” Blood (ASH Annual Meeting Abstracts), 2017;130:4141. [Poster Presentation]

112. Shah N, Ahn K, Litovich C, Sureda A, Smith S, Fenske T, Hamadani M. Outcomes of patients 65 years and older with non-Hodgkin lymphoma receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation compared to patients 55-64 years of age: A CIBMTR analysis. Biology of Blood and Marrow Transplantation. March 2018;24(3):S77-S78. [Oral Presentation]

113. Levis M, Hamadani M, Logan B, Rosales M, Perl A, Devine S, Bahceci E, Chen YB. A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML. J Clin Oncol. 2018;36:(suppl; abstr TPS7075). [Poster Presentation]

114. Hamadani M, Ahn KW, Litovich C, Herve F, Smith S, Fenske T, Boumendil A, Dietrich S, Robinson S, Montoto S, Dreger P, Sureda A. Post-transplant cyclophosphamide (PT-Cy) based haploidentical transplantation (haploHCT) versus matched sibling (MSD) or matched unrelated donor (MUD) reduced intensity conditioning (RIC) HCT for diffuse large b-cell lymphoma (DLBCL): A CIBMTR and EBMT analysis. J Clin Oncol. 2018;36:(suppl; abstr 7056). [Poster Presentation]

115. Hamadani M, Collins G, Samaniego F, Spira A, Davies A, Radford J, Caimi P, Menne T, Boni J, Cruz H, Feingold J, He S, Wuerthner J, Horwitz S. Phase 1 atudy of Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts), 2018;132:928. [Oral Presentation]

116. Epperla N, Ahn K, Litovich C, Kharfan-Dabaja K, Sonali S, Sureda A, Fenske T, Hamadani M. Impact of allogeneic hematopoietic cell transplantation (allo-HCT) on the outcomes of angioimmunoblastic T-cell lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Blood (ASH Annual Meeting Abstracts), 2018;132:969. [Oral Presentation]

117. Collins G, Horwitz S, Davies A, Karnad A, Samaniego F, Spira A, Fields P, Menne T, Boni J, Cruz H, Feingold J, He S, Wuerthner J, Hamadani M. Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based CD25-targetting antibody drug conjugate, in a phase 1 study of relapsed/refractory non-Hodgkin lymphoma shows activity in T-cell lymphoma. Blood (ASH Annual Meeting Abstracts), 2018;132:1658. [Poster Presentation]

118. Dhakal B, Giri S, Levin A, Lisa R, Fenske T, Chhabra S, Shah N, Szabo A, D’Souza A, Pasquini M, Hari P, Hamadani M. Incidence and predictors of 30-day readmissions following autologous hematopoietic cell transplantation (auto-HCT) in the U.S. Blood (ASH Annual Meeting Abstracts), 2018;132:3544. [Poster Presentation]

119. Dhakal B, Giri S, Levin A, Lisa R, Fenske T, Chhabra S, Shah N, Szabo A, D’Souza A, Pasquini M, Hari P, Hamadani M. Association between transplant volumes and 30-day readmission following allogeneic hematopoietic cell transplantation (allo-HCT) in the U.S. Blood (ASH Annual Meeting Abstracts), 2018;132:617. [Poster Presentation]

120. Kanakry J, Ahmed S, Ahn K, Litovich C, Kharfan-Dabaja M, Fenske T, Sureda A, Hamadani M. Post-transplant cyclophosphamide (PTCy)-based haploidentical (Haplo) donor vs. calcineurin-inhibitor (CNI)-based matched related donor (MRD) reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT) for classical Hodgkin lymphoma (cHL). Biology of Blood and Marrow Transplantation. March 2019;25(3):S406–S407. [Poster Presentation]

121. Pidala J, Hamadani M, Dawson P, Alousi A, Jagasia M, Efebera Y, Chhabra S, Pusic I, Holtan S, Ferrara J, Levine J, Anasetti C, Pritchard T, Martens M, Horowitz M, MacMillan M. Sirolimus vs. prednisone as initial systemic therapy for Minnesota standard risk (MN-SR), Ann Arbor 1/2 acute graft-vs-host disease (GVHD): primary results of the multi-center randomized phase II BMT CTN 1501 trial. Biology of Blood and Marrow Transplantation. March 2019;25(3):S50–S51. [Oral Presentation]

122. Chhabra S, Hari P, Visotcky A, Zhu F, Cantrall K, Abedin S, Dhakal B, D’Souza A, Drobyski W, Fenske T, Jerkins J, Rizzo JD, Runaas, Saber W, Shah N, Shaw B, Pasquini M, Hamadani M. Phase I/2 study of ixazomib for chronic graft-versus-host disease (cGVHD) prophylaxis after allogeneic transplantation (alloHCT). Biology of Blood and Marrow Transplantation. March 2019;25(3):S224–S225. [Poster Presentation]

123. Ghosh N., Ahmed S., Litovich C., Ahn K., Khanal M., Kharfan-Dabaja M., Sureda A., Fenske T., Hamadani M.: “Comparison of reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in non-Hodgkin lymphomas (NHL)-a Center for International Blood & Marrow Transplant Research (CIBMTR) analysis.” Blood (ASH Annual Meeting Abstracts), 2019;134:319. [Oral Presentation]

124. Ahmed S., Ghosh N., Litovich C., Ahn K., Khanal M., Kharfan-Dabaja M., Sureda A., Fenske T., Hamadani M.: “Comparison of reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in classical Hodgkin lymphoma-a Center for International Blood & Marrow Transplant Research (CIBMTR) analysis.” Blood (ASH Annual Meeting Abstracts), 2019;134:3318. [Poster Presentation]

125. Jagadeesh D., Majhail N., Yizeng H., Litovich C., Ahn K., Kharfan-Dabaja M., Sureda A., Fenske T., Hamadani M.: “Does addition of rituximab (R) to BEAM conditioning improve outcomes of patients with diffuse large B-cell lymphoma (DLBCL) undergoing autologous hematopoietic cell transplantation (auto-HCT)?” Blood (ASH Annual Meeting Abstracts), 2019;134:785. [Oral Presentation]